topic0
Estrogen [horm, phsu, strd] 0.00451848983708
Men [popg] 0.00430631677381
Acute myocardial infarction [dsyn] 0.00365782117262
N NOS [aapp, imft] 0.00323673900514
Menopause [phsf] 0.00303647971618
Breast Cancer [neop] 0.00301356260661
Benefit [qnco] 0.00290347978687
Myocardial Infarction [dsyn] 0.00272019525434
Estradiol [horm, phsu, strd] 0.00248549391681
Oral [spco] 0.00246589472018
Receive [qlco] 0.00245538403568
coronary [bpoc] 0.00238522005023
Received [qlco] 0.00237538519657
Lipid [lipd] 0.00236349155121
Similar [qlco] 0.00232818544031
Incidence [qnco] 0.00228832245048
placebo [topp] 0.00228594480883
Blood Pressure [orgf] 0.00220085409968
PREVENT [phsu] 0.00210921317797
coronary artery disease [dsyn] 0.00205631318927
Death [orgf] 0.00205057221649
Profile [lbpr] 0.00192510025233
Survival [acty] 0.00190911203491
Stroke [dsyn] 0.00189660649908
Drug Therapy [topp] 0.00184897521815
Decrease [qlco] 0.00182075308967
mg% [qnco] 0.00178720604335
Diabetes [dsyn] 0.00176348338479
Progestin [horm, phsu, strd] 0.00175972925041
Decreased [qnco] 0.00172630044467
randomized [resa] 0.00171283598348
Early [tmco] 0.00171219831234
Combined [qlco] 0.00169643739258
Subject [grup] 0.00163587480142
Drug [phsu] 0.00162466664732
Current [tmco] 0.00160659594056
Diet [food] 0.00160314397271
Measured [qlco] 0.00159849664307
Low density lipoprotein [aapp, bacs, lipd] 0.00158270448782
days [tmco] 0.00157941695392
Cholesterol [bacs, strd] 0.00157351194814
Reported [inpr] 0.0015454255529
Confidence Interval [qnco] 0.00150546808767
Drugs [phsu] 0.00149707554771
High Risk [qlco] 0.00149328235783
Plasma [bdsu] 0.00149201186001
Users [humn] 0.00146066163597
Aged [orga] 0.00143682830535
Daily [tmco] 0.00142372625256
Addition [ftcn] 0.00141123902543
Total Cholesterol [lbpr] 0.00140941567769
Hospital [hcro, mnob] 0.00140608768728
Change [ftcn] 0.00139565870666
Non [ftcn] 0.0013943603177
Four [qnco] 0.00138362821708
considered [idcn] 0.00137160028922
Available [ftcn] 0.00133585978106
low [qlco] 0.00133467128904
Old [tmco] 0.00133433311352
Science [ocdi] 0.00133232473778
Likely [qlco] 0.00133096598331
Overall [inpr] 0.00131935974891
Cases [ftcn] 0.00131038619895
Prevalence [qnco] 0.00130342858687
Known [qlco] 0.0013020626984
Complications [patf] 0.00128219152791
ischaemic heart disease [dsyn] 0.00127349040963
Heart disease [dsyn] 0.00126614710536
Large [qnco] 0.00126473654428
Need [qlco] 0.00125716434238
Association [menp] 0.00125382546887
Induced [ftcn] 0.00125187478392
History [ocdi] 0.00124593815476
mg dl [qnco] 0.00123527769509
diabetic [fndg] 0.00122971283208
Improved [qlco] 0.00121960652272
Diagnosis [fndg] 0.00121529333804
Cardiac [bpoc] 0.00120395006577
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00119660158835
findings [ftcn] 0.00117393576355
Heart [bpoc] 0.00117206823059
development [phsf] 0.00117169891646
Target [ftcn] 0.00117006419325
APPEAR [qlco] 0.00116087019049
Cancer [neop] 0.00115121830107
Combination [qlco] 0.00114209301719
IMPACT [gngm] 0.00113865079819
Young [tmco] 0.00113166143349
Assess [acty] 0.00112011165224
Severe [qlco] 0.00111955793242
Recent [tmco] 0.00111124270329
Independent [idcn] 0.00111087626318
median [spco] 0.00110922951476
Atherosclerosis [dsyn] 0.00110704367906
Several [qnco] 0.00109944346081
Raloxifene [orch, phsu] 0.00109788755476
Range [qnco] 0.00109251232722
Alone [qnco] 0.00108126126156
Well [qlco] 0.0010717455184
symptoms [ftcn] 0.00106850401353
Transdermal [ftcn] 0.00106448224246
weeks [tmco] 0.00104600027995
Osteoporosis [dsyn] 0.00104430909354
mmHg [qnco] 0.00104309350509
acute [tmco] 0.00104290311998
Low Density Lipoprotein Cholesterol [bacs, strd] 0.00104281419058
Information [idcn] 0.00103952670689
Equal [qlco] 0.00103406700837
Following [tmco] 0.00102748395796
Test [lbpr] 0.00101775078125
Marker [clna] 0.00101678491482
Benefits [qnco] 0.00101600979879
Estrogen Replacement Therapy [topp] 0.00101512476285
Dose [qnco] 0.00101454090138
Mechanisms [ftcn] 0.00101419223385
Evaluated [ftcn] 0.00101226353697
Occur [acty] 0.0010120124698
GIVEN [cnce] 0.00100873236431
Insulin [aapp, horm, phsu] 0.00100666047878
Triglycerides [bacs, lipd] 0.00100329366858
Concern [idcn] 0.000994706135243
Common [qnco] 0.000986201698849
Elderly [popg] 0.000981192012252
intervention [hlca] 0.000976976120492
Atrial Fibrillation [patf] 0.0009702641145
Estrogens [horm, phsu, strd] 0.000969046820239
Morbidity [qnco] 0.00096870299232
Identified [qlco] 0.000968393928527
Null [qnco] 0.000967909122405
Prognosis [hlca] 0.000965145822536
Relationship [qlco] 0.000964754842204
Possible [qlco] 0.000962475906235
Replacement [topp] 0.000960597290153
strategies [menp] 0.00095953491679
Onset [qlco] 0.000956872711161
interventions [hlca] 0.000956037647964
Administration [ocac] 0.000955209990048
Needed [qlco] 0.000944361098266
Predictor [idcn] 0.00093225954402
HRT [topp] 0.000931449479804
national [inpr] 0.000929431629813
Individual [popg] 0.000929340437793
Menopausal [phsf] 0.000928744571028
Reducing [qlco] 0.00092473682398
LTD [ortf] 0.000924513398919
Lp(a) [aapp, bacs] 0.000923816994769
Often [tmco] 0.00090866768033
experience [menp] 0.000907183019387
Consecutive [qlco] 0.000906384289967
Relative Risk [qnco] 0.000899157292429
lowering [spco] 0.000896989983671
Agent [chvf] 0.000889514218748
radiotherapy [inpr] 0.000886440406618
Provide [acty] 0.00088547470415
investigated [ftcn] 0.000880560394613
Purpose [ftcn] 0.000872975242306
Adjusted [ftcn] 0.000872470921878
Increasing [ftcn] 0.000869019795232
Cost Effectiveness [qnco] 0.000860229936497
Lipoprotein [aapp, bacs] 0.000856754846494
Odds Ratio [qnco] 0.000854596122854
Medical [ftcn] 0.000853547954476
Main [qlco] 0.000850567930199
recommendations [idcn] 0.000843713205438
Events [evnt] 0.000842252684174
Percent [qnco] 0.000842095613384
I- [inch] 0.000840272574324
setting [ftcn] 0.000839377086723
condition [dsyn] 0.000833040380374
Woman [popg] 0.000829268316324
Evaluation [ftcn] 0.0008209032779
Concentrations [menp] 0.000820894229826
Serum [bdsu] 0.00082010232797
Report [inpr] 0.000820084897375
Specific [qlco] 0.000818994869442
influential [idcn] 0.000813274839611
Sex [orgf] 0.000813203728617
Smoking [inbe] 0.000811146018666
Life [idcn] 0.00080853001159
Select [acty] 0.000805721826522
Future [tmco] 0.000805160088705
Assessed [acty] 0.000803288778355
R- [spco] 0.000800997261069
Clinical Trials [resa] 0.00080013646989
Take [hlca] 0.000799842419214
function [phsf] 0.00079982891524
Parameters [fndg] 0.000799388676647
size [spco] 0.000799261612184
Same [qlco] 0.000796691301871
Issue [fndg] 0.000794370688471
Response [orga] 0.000793658164696
Secondary Prevention [topp] 0.000791737275792
Guidelines [inpr] 0.000790967079542
mg day [qnco] 0.000790631072439
vascular [bpoc] 0.000790459811928
C-reactive protein [aapp, imft] 0.00078540619736
Risks [qlco] 0.000780487206547
Normal [qlco] 0.000778825104171
smokers [fndg] 0.000776532074243
Children [aggp] 0.000775943043365
society [orgt] 0.000775538626474
Make [ftcn] 0.000771241181247
Aspirin [orch, phsu] 0.000769015695073
Literature [inpr] 0.000766623999865
Fasting [fndg] 0.000766147873524
Simvastatin [orch, phsu] 0.000754506219195
Thrombolytic Therapy [topp] 0.000753417826755
Cost [qnco] 0.000751383435633
Late [tmco] 0.000750292286826
Approach [spco] 0.000747826893193
cardiovascular risk factor [dsyn] 0.000746111472073
Quality [qlco] 0.000744522241566
Body Mass Index [diap] 0.000744020732706
Primary [qlco] 0.000740683763128
Initial [tmco] 0.000738766461958
Affect [menp] 0.000737452485292
Past [tmco] 0.000737201423216
Support [medd] 0.000736933985656
Values [qlco] 0.000736155968584
H+ [elii] 0.000735438366809
Occurred [acty] 0.000734566542884
Risk factor [qnco] 0.000734435501083
Cohort [popg] 0.000732582466559
Five [qnco] 0.00073063628077
Half [qnco] 0.000729284421675
Selective Estrogen Receptor Modulators [horm, phsu] 0.000726672299207
Controlled [ftcn] 0.000726200504613
In [qnco] 0.000725394027773
objectives [inpr] 0.000724835747112
American [popg] 0.000724473104373
Therapeutic [topp] 0.000719208475795
Previous [tmco] 0.000718903385215
Fatal [qlco] 0.000718278028531
Case [ftcn] 0.000716935601041
Established [qlco] 0.000716490153638
Safety [hcpp] 0.000716466028414
Examined [fndg] 0.000715048831038
reviewed [inpr] 0.000708095595379
Myocardial [spco] 0.000705631270592
participants [popg] 0.00070374520278
Conduct [inbe] 0.000703667916892
Cholesterol, LDL [bacs, strd] 0.00070347311
Improvement [cnce] 0.000702249769637
Progestagen [horm, phsu, strd] 0.000700814761376
practice [menp] 0.000700402539294
Now [tmco] 0.000697737723157
Obesity [dsyn] 0.000696074187723
hypertensive [fndg] 0.000692532048043
Favorable [qlco] 0.000691886345485
Mechanism [ftcn] 0.000691804543237
Recommended [idcn] 0.000690768218678
Event [evnt] 0.000688600732469
Compliance [qnco] 0.000687670908713
Progesterone [horm, phsu, strd] 0.000686590270191
Heart failure [dsyn] 0.000683917078858
Long [qlco] 0.00068359466166
Systolic blood pressure [clna] 0.000677913406309
Regimen [topp] 0.000675534183351
Knowledge [inpr] 0.000673505928247
Continuous [idcn] 0.000672229557887
Exercise [dora] 0.000671816749708
variables [qlco] 0.000671142848445
Sample [sbst] 0.000669272135143
Leading [tmco] 0.000667905990967
Hormone [horm] 0.000665060444101
Presence [topp] 0.00066240931261
Lipids [lipd] 0.00065941204297
Indicated [fndg] 0.000659155763543
Effectiveness [qlco] 0.000658677222286
Appropriate [qlco] 0.000656424093357
Diseases [dsyn] 0.000654993022738
Ratio [qnco] 0.000652635502495
Contribute [acty] 0.000651600841909
Characteristics [qlco] 0.000648904235552
Tamoxifen [orch, phsu] 0.000647267082817
Single [popg] 0.00064550210608
Care [acty] 0.000645432942214
g% [qnco] 0.000643970195013
Administered [ftcn] 0.000641902382099
Infarction [patf] 0.000639258447901
Phase [tmco] 0.000638253710896
Post-Menopause [orgf] 0.000635150722272
Measure [qnco] 0.000633184252039
Treatments [topp] 0.000632691073751
Strong [qlco] 0.000632256918738
Persons [popg] 0.000631186866925
Fibrinogen [aapp, bacs, phsu] 0.000629660167989
Initiate [idcn] 0.000628635917991
Dependent [qlco] 0.000626077981161
Average [qnco] 0.000625746965429
Surgery [bmod] 0.000625091650474
Comparison [acty] 0.000624980858732
Duration [tmco] 0.000621019464133
Article [inpr] 0.000620104066785
Various [irda] 0.000619745170858
activity [dora] 0.000619101061882
Start [tmco] 0.000618207579306
Prognostic Factor [clna] 0.000617893027528
Community [geoa] 0.000617823207267
prospective [resa] 0.000617342509101
Better [qlco] 0.000616599262299
Equine [mamm] 0.000615628276929
Progestins [horm, phsu, strd] 0.000615404116729
System [ftcn] 0.00061374174262
Education [edac] 0.000613262796322
prognostic [inpr] 0.000610978041104
Statins [orch, phsu] 0.00061048459642
Insulin Sensitivity [patf] 0.000608423356098
regimens [inpr] 0.000606841275719
Currently [tmco] 0.000605976674878
Diabetes Mellitus [dsyn] 0.000603393869956
Plus [qlco] 0.000603373638449
properties [qlco] 0.000600734385511
Hypercholesterolaemia [dsyn] 0.00060054518131
Small [qnco] 0.000597554165667
Second [qnco] 0.000596461329005
Died [orgf] 0.000595687738279
Human [humn] 0.000594987677373
Dietary [food] 0.000593989505465
Recently [tmco] 0.000593463187152
lack [qlco] 0.000591516424049
Cardiology [bmod] 0.000587606253893
Type [qlco] 0.000585347598143
Syndromes, Acute Coronary [dsyn] 0.000582292212442
Ischaemic [ftcn] 0.000582033804214
Physicians [prog] 0.000581061166786
confirmed [qlco] 0.000580789210853
Endothelial [tisu] 0.000579983547341
Costs [qnco] 0.000577548022973
Process [bpoc] 0.000576747503833
Few [qnco] 0.000575427937827
Negative [qlco] 0.000575118121389
Glucose [bacs, carb, phsu] 0.000574121889732
Alternative [cnce] 0.000574085302363
Seen [qlco] 0.000572272844617
Altered [ftcn] 0.000571528012575
Part [spco] 0.000571419221651
Defined [cnce] 0.000571283319111
Beta-Blockers [phsu] 0.000569227407904
Additional [ftcn] 0.000568490061257
cardiovascular events [fndg] 0.000566654373173
.BETA.-Carotene [orch, phsu, vita] 0.00056375010746
Standard [qlco] 0.000561927176436
Relative [famg] 0.00056037352435
Estrogen Replacement [topp] 0.000560329877471
Congestive heart failure [dsyn] 0.000558816708757
Published [ocac] 0.000557900812128
Severity [qlco] 0.000557872739627
progression [patf] 0.000557850485541
Extent [spco] 0.000556688081567
DOUBLE BLIND [resa] 0.000555397582956
reductions [npop] 0.000553899062833
Direct [qlco] 0.000552161816267
Contrast [qlco] 0.000551946829524
Control Group [grup] 0.000548533155031
distribution [idcn] 0.000548439489008
mmol/L [qnco] 0.000547865685519
Expression [topp] 0.000547601751113
United States [geoa] 0.000545790161072
Compare [acty] 0.000545622274883
Compound [qlco] 0.000545392837184
Physical activity [dora] 0.000544837699974
Out [spco] 0.000544502873535
Presented [idcn] 0.000540540389458
hormone replacement [topp] 0.000538589189299
Doses [qnco] 0.000538502921121
Obtained [ftcn] 0.000538238926142
medroxyprogesterone acetate [horm, phsu, strd] 0.000537451442839
month [tmco] 0.000537147530279
Thrombolysis [clna] 0.000536766558774
Frequently [tmco] 0.000536717407177
Class [inpr] 0.000534641668311
Action [ftcn] 0.000534330338288
Lipoproteins [aapp, bacs] 0.00053293365449
adverse effects [ftcn] 0.000532093458539
Analyzed [resa] 0.00052843417692
Model [inpr] 0.000524126288984
Central [spco] 0.000521082373097
Method [inpr] 0.000519809589162
Hormone Replacement Therapy, Post-Menopausal [topp] 0.000516790933556
Medication [phsu] 0.000516249187207
???lead [elii, hops] 0.000515700959736
Observational Study [resa] 0.000511119643626
Documented [hlca] 0.000510999827246
absence [qnco] 0.000509509025655
Delay [tmco] 0.000507952952168
Perimenopausal [tmco] 0.000503110697909
Male [fndg] 0.000503095204822
Short-term [tmco] 0.000501683310488
Critical [qlco] 0.000501191293309
Adjustment [inbe] 0.000501139006816
Stage [tmco] 0.000499776377585
Discharge [bdsu] 0.000498736675273
People [popg] 0.000497586839298
Link [inpr] 0.000496192068221
Goal [inpr] 0.000495166984617
Third [qnco] 0.000495048779944
Required [ftcn] 0.000495013820545
Ketamine [orch, phsu] 0.000494202312579
Limited [ftcn] 0.00049343361694
topic1
Estrogen [horm, phsu, strd] 0.00607026994535
placebo [topp] 0.00315337577294
Menopause [phsf] 0.00312351351315
Acute myocardial infarction [dsyn] 0.00289269983432
Lipid [lipd] 0.00251887061109
Oral [spco] 0.0024221077484
Men [popg] 0.00241858355332
Plasma [bdsu] 0.00238900966246
coronary [bpoc] 0.00232384291486
Subject [grup] 0.00224893726084
Myocardial Infarction [dsyn] 0.00214326910563
Estradiol [horm, phsu, strd] 0.00212325359824
Breast Cancer [neop] 0.00211548321516
Old [tmco] 0.0020985010725
coronary artery disease [dsyn] 0.00209536263259
N NOS [aapp, imft] 0.00207229799863
Blood Pressure [orgf] 0.00206032063317
randomized [resa] 0.00205722823872
Cholesterol [bacs, strd] 0.00195805414563
Benefit [qnco] 0.0019307885386
Osteoporosis [dsyn] 0.00187022741754
Stroke [dsyn] 0.00186763508766
Incidence [qnco] 0.00185490687115
Reported [inpr] 0.00180322790523
Confidence Interval [qnco] 0.00179676984583
Receive [qlco] 0.00177188303871
Change [ftcn] 0.00171924888481
development [phsf] 0.001703248858
Raloxifene [orch, phsu] 0.00166451729174
Combined [qlco] 0.00165888244182
Well [qlco] 0.00162497766942
intervention [hlca] 0.0016192060188
Current [tmco] 0.00161327628024
Decreased [qnco] 0.00160651025453
Profile [lbpr] 0.00160124380289
Drug [phsu] 0.00159864561546
Measured [qlco] 0.00156676266919
Low density lipoprotein [aapp, bacs, lipd] 0.00156405952706
Recent [tmco] 0.00155854672927
Drug Therapy [topp] 0.00152833682667
Likely [qlco] 0.00152121064201
mg% [qnco] 0.00151797676637
days [tmco] 0.00151249503598
Decrease [qlco] 0.00149685824151
Available [ftcn] 0.00147232364922
Similar [qlco] 0.00147139789464
low [qlco] 0.00145335978583
considered [idcn] 0.00144461697645
Progestin [horm, phsu, strd] 0.00143710508356
Heart [bpoc] 0.00143275250523
Drugs [phsu] 0.00142914335287
Heart disease [dsyn] 0.00142118438368
Equal [qlco] 0.00141458370111
Elderly [popg] 0.00140860533508
Diabetes [dsyn] 0.00139656710439
Several [qnco] 0.00139364221888
symptoms [ftcn] 0.00138662141553
Death [orgf] 0.00137237833631
Need [qlco] 0.0013654626717
Simvastatin [orch, phsu] 0.00135378746183
Relationship [qlco] 0.00134296466523
Non [ftcn] 0.00131047961297
Diagnosis [fndg] 0.00131031499592
Cardiac [bpoc] 0.00130190447877
Daily [tmco] 0.00129360060863
Dose [qnco] 0.00129083024699
acute [tmco] 0.00128596488757
Diet [food] 0.00128400175347
PREVENT [phsu] 0.00127991827269
Received [qlco] 0.00127975537437
Cases [ftcn] 0.00127973434792
Users [humn] 0.00127194747099
Prevalence [qnco] 0.00126256298773
Secondary Prevention [topp] 0.001262083482
Smoking [inbe] 0.00126178585816
Insulin [aapp, horm, phsu] 0.0012542308725
Individual [popg] 0.0012431503644
Target [ftcn] 0.00124199923305
Estrogens [horm, phsu, strd] 0.00122476942611
ischaemic heart disease [dsyn] 0.00122268192969
Alone [qnco] 0.00121782912968
Combination [qlco] 0.00120987514655
Take [hlca] 0.00119510613252
Provide [acty] 0.00119490260507
Science [ocdi] 0.00118829984033
Atherosclerosis [dsyn] 0.00118695375739
Early [tmco] 0.00118130749847
APPEAR [qlco] 0.00117855822432
Aged [orga] 0.00116066591415
Large [qnco] 0.00115669222688
Guidelines [inpr] 0.00115553417491
Estrogen Replacement Therapy [topp] 0.00115444840353
progression [patf] 0.00115396648642
High Risk [qlco] 0.00114370897508
condition [dsyn] 0.00114183709059
Triglycerides [bacs, lipd] 0.00113319027344
Progestagen [horm, phsu, strd] 0.00113310031493
Null [qnco] 0.00113127781984
Common [qnco] 0.00112982557986
Lp(a) [aapp, bacs] 0.00112746798088
Young [tmco] 0.00112113312317
Phase [tmco] 0.00110293171571
Specific [qlco] 0.00110180075827
mg dl [qnco] 0.00109061813902
Known [qlco] 0.00108875300038
Total Cholesterol [lbpr] 0.00108618623811
findings [ftcn] 0.00108433297578
Aspirin [orch, phsu] 0.00108347475441
Possible [qlco] 0.00107394735153
Addition [ftcn] 0.00107387683166
Identified [qlco] 0.0010712903323
Main [qlco] 0.00106634355822
Agent [chvf] 0.00105437927705
Four [qnco] 0.00105007102738
Events [evnt] 0.00104972576898
hypertensive [fndg] 0.00104412114802
Association [menp] 0.0010346055655
Same [qlco] 0.00103289069618
Overall [inpr] 0.00103047636239
Quality [qlco] 0.00102967503983
Information [idcn] 0.00102647814681
Improved [qlco] 0.00101957869499
Hospital [hcro, mnob] 0.00101468424108
mmHg [qnco] 0.00101378099573
Low Density Lipoprotein Cholesterol [bacs, strd] 0.00101363724871
Serum [bdsu] 0.00101305820726
GIVEN [cnce] 0.00101166638863
median [spco] 0.0010115790461
Atrial Fibrillation [patf] 0.00100569002964
Occur [acty] 0.00100245354938
Complications [patf] 0.000999247717597
Induced [ftcn] 0.00098969352759
LTD [ortf] 0.000980103201921
Parameters [fndg] 0.000972704129211
Medical [ftcn] 0.000968391267292
Knowledge [inpr] 0.000960285594123
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000954993672934
Often [tmco] 0.00095454936909
In [qnco] 0.000953633010608
lowering [spco] 0.000953192427673
Marker [clna] 0.000952643303543
Range [qnco] 0.00095178126649
Life [idcn] 0.000950280455291
Clinical Trials [resa] 0.000948028206516
HRT [topp] 0.000946127167667
Assess [acty] 0.000945891543318
Assessed [acty] 0.00094405207444
diabetic [fndg] 0.000941817349952
Benefits [qnco] 0.000940815238831
radiotherapy [inpr] 0.000937026739246
Safety [hcpp] 0.000934697243751
History [ocdi] 0.000933284867499
Conduct [inbe] 0.000932830644979
objectives [inpr] 0.000930188422286
recommendations [idcn] 0.000928343630093
Obesity [dsyn] 0.000927484520064
Cholesterol, LDL [bacs, strd] 0.000925573089573
Prognosis [hlca] 0.000923053884062
Following [tmco] 0.000914036119414
Relative Risk [qnco] 0.000903563791494
Morbidity [qnco] 0.000889447895202
Characteristics [qlco] 0.000889047592168
Average [qnco] 0.000887856401446
Five [qnco] 0.000887807843798
Post-Menopause [orgf] 0.000882874705504
Therapeutic [topp] 0.000881621354823
Transdermal [ftcn] 0.000880774058141
Care [acty] 0.000879578936321
Survival [acty] 0.000876805258116
Cost Effectiveness [qnco] 0.000876762359428
Response [orga] 0.000872083194
Odds Ratio [qnco] 0.000870653829308
Test [lbpr] 0.000867520141223
Children [aggp] 0.000863829486845
Cancer [neop] 0.000859367675503
Examined [fndg] 0.000856090199632
Currently [tmco] 0.000851344901635
size [spco] 0.000849593978889
Independent [idcn] 0.000843025465626
Established [qlco] 0.000836480631376
Mechanisms [ftcn] 0.000836470699805
Presence [topp] 0.000835054319655
Percent [qnco] 0.000833876393928
Continuous [idcn] 0.000831630261703
Compliance [qnco] 0.000827648564345
Progesterone [horm, phsu, strd] 0.000827450831555
society [orgt] 0.000823496111823
Select [acty] 0.000822664335459
Model [inpr] 0.000822232490366
Evaluated [ftcn] 0.000819713076658
experience [menp] 0.000818963964843
Type [qlco] 0.00081211903216
Risk factor [qnco] 0.000810712813212
Concentrations [menp] 0.000807663360434
Diastolic blood pressure [clna] 0.000807631609037
Previous [tmco] 0.000806593985094
Values [qlco] 0.000799688824126
Out [spco] 0.00079922099868
Costs [qnco] 0.000796101322253
Replacement [topp] 0.000790310032053
weeks [tmco] 0.000786573000511
Various [irda] 0.000784183103994
Ireland [geoa] 0.000780657593955
setting [ftcn] 0.000779733372272
Event [evnt] 0.000778667699551
strategies [menp] 0.000777429800463
Contribute [acty] 0.000770670132029
Cohort [popg] 0.000770425030201
variables [qlco] 0.000769714191147
Treatments [topp] 0.000768188979518
Future [tmco] 0.000766015975987
Exercise [dora] 0.000763754932243
Predictor [idcn] 0.000763459973201
Primary [qlco] 0.000763097259262
function [phsf] 0.000762116958037
Needed [qlco] 0.00076194353681
Process [bpoc] 0.000757777399059
R- [spco] 0.000756119696488
Improvement [cnce] 0.000755339168233
Affect [menp] 0.000751834486378
Hypercholesterolaemia [dsyn] 0.000750309095033
Relative [famg] 0.000748833762897
Venous Thromboembolism [patf] 0.000745814246867
Plus [qlco] 0.000744261775885
Literature [inpr] 0.000737020296444
Severe [qlco] 0.00073587186118
month [tmco] 0.000735725458486
Report [inpr] 0.000730681618867
Seen [qlco] 0.000725506477618
Late [tmco] 0.000725329037562
interventions [hlca] 0.000725243393308
Adjustment [inbe] 0.000723923506775
Sex [orgf] 0.000723854878686
Method [inpr] 0.000719095079961
Selective Estrogen Receptor Modulators [horm, phsu] 0.000718331799589
IMPACT [gngm] 0.000711876781743
Evaluation [ftcn] 0.000710107908155
Body Mass Index [diap] 0.000707394003813
influential [idcn] 0.000705740421517
Article [inpr] 0.000705352954399
Estimated [qnco] 0.000704965033441
Make [ftcn] 0.000700092201127
Thrombolytic Therapy [topp] 0.000698866837141
Duration [tmco] 0.000698013411079
Increasing [ftcn] 0.000693535976616
Central [spco] 0.000692513350144
Action [ftcn] 0.000692086613866
Prognostic Factor [clna] 0.000691425456101
I- [inch] 0.000690669933363
Standard [qlco] 0.000688483800896
investigated [ftcn] 0.00068691270322
Analyzed [resa] 0.000686835503898
Now [tmco] 0.000685274468434
Fasting [fndg] 0.000684610748239
Part [spco] 0.000683315308341
Interaction [ftcn] 0.000681810208731
Observational Study [resa] 0.000680075584238
Recently [tmco] 0.000678112405815
Obtained [ftcn] 0.000676139095136
Support [medd] 0.000674219034816
Reducing [qlco] 0.000673209152152
Persons [popg] 0.000672639684847
mg day [qnco] 0.000671441146257
Compare [acty] 0.000669068995357
Calcium [bacs, elii, phsu] 0.000666537932029
prospective [resa] 0.000665340168279
Surgery [bmod] 0.000664608509576
atorvastatin [orch, phsu] 0.000660718361621
Compound [qlco] 0.000660606249911
Dependent [qlco] 0.000659670992611
Adults [aggp] 0.000659300434158
Diseases [dsyn] 0.000658580329692
Chemoprevention [topp] 0.00065677820717
Case [ftcn] 0.000656036325796
Menopausal [phsf] 0.000652548783353
Fatal [qlco] 0.000652504080234
Lipoprotein [aapp, bacs] 0.000650583943896
Onset [qlco] 0.000650460488353
Purpose [ftcn] 0.000648252778824
reviewed [inpr] 0.000648163587001
American [popg] 0.000645669185506
Administered [ftcn] 0.000644739438049
Risks [qlco] 0.000644720679699
United States [geoa] 0.0006443181585
Favorable [qlco] 0.000643128325227
Diabetes Mellitus [dsyn] 0.000639193615226
Single [popg] 0.000638060661926
Ischaemic [ftcn] 0.000637756026581
cardiovascular risk factor [dsyn] 0.000636706569854
Occurred [acty] 0.000633506623255
vascular [bpoc] 0.000633467080818
Alternative [cnce] 0.000629571035578
Community [geoa] 0.0006251487868
g% [qnco] 0.000624516730578
Initial [tmco] 0.000623591122125
Effectiveness [qlco] 0.000619932838478
Regimen [topp] 0.000617719226635
Approach [spco] 0.000614472429587
lack [qlco] 0.000614450301478
Past [tmco] 0.00061431617885
Second [qnco] 0.000613998022554
Appropriate [qlco] 0.000613746316693
Heart failure [dsyn] 0.000613494086505
Long [qlco] 0.000613069690198
weight [orga] 0.000613024645238
activity [dora] 0.000610850162515
mmol/L [qnco] 0.000606510328762
national [inpr] 0.000606315196423
Physicians [prog] 0.000605756348019
Education [edac] 0.000605072355607
Leading [tmco] 0.000602871666405
Fibrinogen [aapp, bacs, phsu] 0.000601034237915
Cycle [tmco] 0.000600306219829
Expected [idcn] 0.000598899556273
C-reactive protein [aapp, imft] 0.000597675460265
Comparison [acty] 0.000597641563408
Direct [qlco] 0.000596102182805
Congestive heart failure [dsyn] 0.000595159153813
Correlated [qlco] 0.000591812405577
Control Group [grup] 0.000590577143054
Seven [qnco] 0.000590034479616
Status [qlco] 0.000590007836245
smokers [fndg] 0.000585050968995
Administration [ocac] 0.000582671033209
Woman [popg] 0.000582215039406
DOUBLE BLIND [resa] 0.0005804716878
Strong [qlco] 0.000579613783896
Lipids [lipd] 0.000579482088463
Glucose [bacs, carb, phsu] 0.000579079236541
Extent [spco] 0.000577739522814
Consecutive [qlco] 0.00057745037151
Measure [qnco] 0.000574516621692
Dietary [food] 0.000573234822418
Adjusted [ftcn] 0.00056733186211
Then [tmco] 0.000566893390472
Statins [orch, phsu] 0.000566124660037
Physical activity [dora] 0.000564202196091
Female [fndg] 0.000562885890072
Issue [fndg] 0.00056273342202
Never [tmco] 0.000560354471328
Concern [idcn] 0.000559689874562
Program [cnce] 0.000558450466877
Complex [qlco] 0.00055646126666
cardiovascular events [fndg] 0.000555216022354
Male [fndg] 0.000551658660403
Cost [qnco] 0.00055070098668
Sequential [idcn] 0.000550299792612
Human [humn] 0.000547105444421
properties [qlco] 0.0005456866279
mediated [socb] 0.000542474277531
admitted [hlca] 0.000542322682352
Systolic blood pressure [clna] 0.000541493518942
Elevated [qlco] 0.000540930703692
Breast [bpoc] 0.000539762941188
Mechanism [ftcn] 0.00053892838554
Thrombolysis [clna] 0.000538136384416
Hormone Replacement Therapy, Post-Menopausal [topp] 0.000536772356885
Tamoxifen [orch, phsu] 0.000535708359826
Limited [ftcn] 0.000535249026339
hormone replacement [topp] 0.000533909838452
Perimenopausal [tmco] 0.000531681759419
participants [popg] 0.00053096219727
Class [inpr] 0.000529859175352
Contrast [qlco] 0.000528881480109
Start [tmco] 0.000526977104468
Medication [phsu] 0.000525752943783
medroxyprogesterone acetate [horm, phsu, strd] 0.000525274143005
Very [qlco] 0.000525233935402
Detection [topp] 0.000525049081228
Ratio [qnco] 0.000524992511006
H+ [elii] 0.000523947253986
Better [qlco] 0.000523020875278
Sclerotherapy [topp] 0.000522876230023
Small [qnco] 0.000522308973549
Normal [qlco] 0.000520434969724
Supplementation [topp] 0.000519621142273
Published [ocac] 0.000517541089307
Little NOS [cgab, dsyn] 0.00051680288689
.BETA.-Carotene [orch, phsu, vita] 0.000515688186932
secondary [neop] 0.000514158717923
Few [qnco] 0.000512918968163
arrested [dsyn] 0.000511239562986
Echocardiography [diap] 0.000510953679306
???lead [elii, hops] 0.00050885010087
Eight [qnco] 0.000508815898326
Ii [aapp] 0.000508788923085
confirmed [qlco] 0.000506640386052
adverse effects [ftcn] 0.000506534731455
Cholesterol, HDL [bacs, lipd] 0.000506108265103
Frequent [tmco] 0.000504712878372
Loss [qnco] 0.000504226742833
System [ftcn] 0.000503615025666
practice [menp] 0.000501766414558
Recommended [idcn] 0.000499057549094
prescribed [hlca] 0.000498960604843
Conjugated estrogen [horm, phsu, strd] 0.000498430283128
Link [inpr] 0.00049752239265
Additional [ftcn] 0.000495689071611
Negative [qlco] 0.000494881193812
Third [qnco] 0.000492002980644
topic2
Men [popg] 0.00371128222949
Acute myocardial infarction [dsyn] 0.00328803993869
Estrogen [horm, phsu, strd] 0.00305786911672
coronary [bpoc] 0.00288007157094
placebo [topp] 0.00282264993182
Subject [grup] 0.00269768778901
Menopause [phsf] 0.00262272627471
Benefit [qnco] 0.00260144942455
Blood Pressure [orgf] 0.00246175768929
N NOS [aapp, imft] 0.00225400159041
Survival [acty] 0.00224909190675
Incidence [qnco] 0.00224654961341
Similar [qlco] 0.00222545320544
Breast Cancer [neop] 0.00216591318905
Estradiol [horm, phsu, strd] 0.00213737302024
Combined [qlco] 0.00200281486462
randomized [resa] 0.00199326098446
Common [qnco] 0.00190794596881
Non [ftcn] 0.00184043854869
Decrease [qlco] 0.00181287964614
Drug [phsu] 0.00179709176309
coronary artery disease [dsyn] 0.00179140809545
Measured [qlco] 0.00176476381006
Possible [qlco] 0.0017600971794
Raloxifene [orch, phsu] 0.00175775897481
Myocardial Infarction [dsyn] 0.00175075987418
Current [tmco] 0.00174748234128
Plasma [bdsu] 0.00174333690735
Cases [ftcn] 0.00171366395457
Early [tmco] 0.0017122907926
Oral [spco] 0.00169426084378
Receive [qlco] 0.00169425341166
Lipid [lipd] 0.00169100256543
Overall [inpr] 0.00167737346586
Received [qlco] 0.00164619055235
Change [ftcn] 0.00161148670684
Progestin [horm, phsu, strd] 0.00158884629385
Several [qnco] 0.00158451558656
Profile [lbpr] 0.00158155122694
Drugs [phsu] 0.0015762377004
Death [orgf] 0.00157470979307
Available [ftcn] 0.00155829498981
Recent [tmco] 0.00155717997919
development [phsf] 0.00155687871077
mg% [qnco] 0.00154131233153
Range [qnco] 0.00153764240388
Decreased [qnco] 0.0015366151314
Reported [inpr] 0.00153229770423
Old [tmco] 0.00151064029655
ischaemic heart disease [dsyn] 0.00150803750471
Prevalence [qnco] 0.00149293775636
Atherosclerosis [dsyn] 0.00147072281592
Stroke [dsyn] 0.00146268509928
Alone [qnco] 0.00146262761743
Heart [bpoc] 0.00144303968355
low [qlco] 0.00143461749907
Assess [acty] 0.00143158404324
Target [ftcn] 0.00143132441571
High Risk [qlco] 0.00141814838182
PREVENT [phsu] 0.00140482199862
Hospital [hcro, mnob] 0.0013939165386
Benefits [qnco] 0.00137446267906
Improved [qlco] 0.00137407299971
Diet [food] 0.0013691279118
Diabetes [dsyn] 0.00135546056291
Large [qnco] 0.00135397319627
Sex [orgf] 0.00132950802643
Drug Therapy [topp] 0.0013092627851
Likely [qlco] 0.00130341118198
Heart disease [dsyn] 0.00129989459499
Individual [popg] 0.00128467689087
Induced [ftcn] 0.00126415744056
Events [evnt] 0.0012575689429
Combination [qlco] 0.00124803000614
symptoms [ftcn] 0.00123667841376
median [spco] 0.00123214844681
Improvement [cnce] 0.00122836802202
Users [humn] 0.00122233932928
Independent [idcn] 0.00121758711083
Well [qlco] 0.0012159706591
APPEAR [qlco] 0.00121309731186
Aged [orga] 0.00120624262508
strategies [menp] 0.00120100000128
Total Cholesterol [lbpr] 0.00119534891714
Cholesterol [bacs, strd] 0.00118817623521
Dose [qnco] 0.00118553767755
acute [tmco] 0.00117847245863
Main [qlco] 0.00117480531098
Osteoporosis [dsyn] 0.00117320399788
Diagnosis [fndg] 0.00116997002658
mg dl [qnco] 0.00116211282082
days [tmco] 0.00115229434569
Complications [patf] 0.00115065676408
practice [menp] 0.00114980263577
Cardiac [bpoc] 0.00114764498695
Agent [chvf] 0.00113525154329
Confidence Interval [qnco] 0.00112343020048
Triglycerides [bacs, lipd] 0.00112032582264
considered [idcn] 0.00111906327074
mmHg [qnco] 0.00110720053149
Atrial Fibrillation [patf] 0.00110617980611
weeks [tmco] 0.00110146177374
Cholesterol, LDL [bacs, strd] 0.00109853521353
Equal [qlco] 0.00107893433794
radiotherapy [inpr] 0.00106538518452
Known [qlco] 0.00106513839418
Elderly [popg] 0.00105294500887
hypertensive [fndg] 0.00104752078378
Relative Risk [qnco] 0.00104594130723
Association [menp] 0.00104101606478
Estrogens [horm, phsu, strd] 0.00103977009611
Science [ocdi] 0.00103859357367
Severe [qlco] 0.00103373580489
Daily [tmco] 0.00103262997578
recommendations [idcn] 0.00103105509374
Assessed [acty] 0.00102538955619
Low density lipoprotein [aapp, bacs, lipd] 0.00102060773244
Information [idcn] 0.00101898872832
diabetic [fndg] 0.00101565767256
Percent [qnco] 0.00101282226925
Cancer [neop] 0.00100973111957
Specific [qlco] 0.00100896090431
History [ocdi] 0.00100600511648
Response [orga] 0.0010008187948
Conduct [inbe] 0.000998015923896
Insulin [aapp, horm, phsu] 0.000992956088375
intervention [hlca] 0.000987368725135
Guidelines [inpr] 0.000985808251778
IMPACT [gngm] 0.000984095543714
Primary [qlco] 0.000979149998183
Second [qnco] 0.000977604886609
Relationship [qlco] 0.000975305436218
Clinical Trials [resa] 0.000970393454811
Average [qnco] 0.000967180879141
cardiovascular risk factor [dsyn] 0.000964119462081
Take [hlca] 0.000964099092728
Estrogen Replacement Therapy [topp] 0.000963516257907
Following [tmco] 0.000962593068859
society [orgt] 0.000958379491885
Presence [topp] 0.000955381079263
lowering [spco] 0.000954110060432
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000950559410982
Smoking [inbe] 0.000945137341704
I- [inch] 0.000944644828413
Same [qlco] 0.000943226805273
LTD [ortf] 0.000935792913647
Need [qlco] 0.000932029619138
Often [tmco] 0.000931687962766
Obesity [dsyn] 0.000925324504358
findings [ftcn] 0.000921534381331
Concentrations [menp] 0.000914590350824
Young [tmco] 0.000908234665893
Marker [clna] 0.000908111751881
Care [acty] 0.000902209368674
Aspirin [orch, phsu] 0.000895188529402
Increasing [ftcn] 0.000894880895469
Medical [ftcn] 0.000889612818294
Make [ftcn] 0.00088816056879
Purpose [ftcn] 0.000885780181982
HRT [topp] 0.000885188150882
Select [acty] 0.000883421996053
Addition [ftcn] 0.00088324817702
Ireland [geoa] 0.000882797933237
Approach [spco] 0.000880141723342
experience [menp] 0.000875916633441
Transdermal [ftcn] 0.000874445885263
Obtained [ftcn] 0.000869680614546
Parameters [fndg] 0.000866641155729
Evaluated [ftcn] 0.000865156920097
Adjusted [ftcn] 0.0008649812091
Menopausal [phsf] 0.000864453247361
Effectiveness [qlco] 0.000862118865512
Predictor [idcn] 0.00086113881023
Better [qlco] 0.00085739413412
Examined [fndg] 0.000856663074217
Lp(a) [aapp, bacs] 0.000851226143844
Values [qlco] 0.000850314796657
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000845164812902
Children [aggp] 0.000844810925494
Affect [menp] 0.000842105973106
Quality [qlco] 0.000838579663147
Mechanisms [ftcn] 0.000835144230029
condition [dsyn] 0.00083014660527
setting [ftcn] 0.000825222338494
Needed [qlco] 0.000819692120133
Normal [qlco] 0.00081680074655
Process [bpoc] 0.000816581461229
Future [tmco] 0.000815311374464
reviewed [inpr] 0.000814694952139
Body Mass Index [diap] 0.000811488699626
Adults [aggp] 0.000810855874391
Safety [hcpp] 0.000808849953977
Knowledge [inpr] 0.000806652271414
GIVEN [cnce] 0.000798552362838
Progestins [horm, phsu, strd] 0.000796542612223
Heart failure [dsyn] 0.000795355959206
In [qnco] 0.000795138170456
Evaluation [ftcn] 0.000792444646713
Selective Estrogen Receptor Modulators [horm, phsu] 0.000790045704319
national [inpr] 0.000785737566752
Continuous [idcn] 0.000782429892106
Exercise [dora] 0.000781703291142
Risk factor [qnco] 0.000778170272616
activity [dora] 0.000773890682385
Leading [tmco] 0.000772297571293
Life [idcn] 0.000770737256324
Breast [bpoc] 0.000769660633924
Dependent [qlco] 0.000760550552234
Established [qlco] 0.000758079535544
Risks [qlco] 0.000756042568175
Duration [tmco] 0.000754846767881
Onset [qlco] 0.000752830548912
Ratio [qnco] 0.000751530826575
C-reactive protein [aapp, imft] 0.000751005577457
Prognosis [hlca] 0.000750283389197
Infarction [patf] 0.000747655350642
Secondary Prevention [topp] 0.000746919646419
Conjugated estrogen [horm, phsu, strd] 0.000743784476722
Physical activity [dora] 0.000741438283281
Part [spco] 0.000741231117975
Literature [inpr] 0.000741217261218
Morbidity [qnco] 0.000738498053684
influential [idcn] 0.000737776711173
Hypercholesterolaemia [dsyn] 0.000736653052909
Lipids [lipd] 0.000732425259638
Estimated [qnco] 0.000730952215571
participants [popg] 0.000730838461399
Various [irda] 0.000727655575405
Congestive heart failure [dsyn] 0.000727612556512
Thrombolytic Therapy [topp] 0.000724021861048
Regimen [topp] 0.000723249456029
Replacement [topp] 0.00072282337828
lack [qlco] 0.000719863189353
Therapeutic [topp] 0.000716325428219
Four [qnco] 0.000716229010641
interventions [hlca] 0.000716089554912
Null [qnco] 0.000714767308031
Occur [acty] 0.000714701428265
Indicated [fndg] 0.000713887672699
Reducing [qlco] 0.000710820117001
Hormone [horm] 0.000706393653571
Cost Effectiveness [qnco] 0.00070503950294
size [spco] 0.000704458574764
Case [ftcn] 0.000703334326126
United States [geoa] 0.000703286062174
Provide [acty] 0.000701556289253
Serum [bdsu] 0.000700871823802
Lipoprotein [aapp, bacs] 0.00069912832036
Plus [qlco] 0.000697098903789
Controlled [ftcn] 0.00069391325731
Systolic blood pressure [clna] 0.000688954994791
cardiovascular events [fndg] 0.000688375062441
function [phsf] 0.000687746444495
prospective [resa] 0.000682857686264
Post-Menopause [orgf] 0.000680031622988
Persons [popg] 0.000675677719197
g% [qnco] 0.000675547733622
variables [qlco] 0.000672609460798
Venous Thromboembolism [patf] 0.000671810445832
Few [qnco] 0.000670303695456
Support [medd] 0.000669654007455
Tamoxifen [orch, phsu] 0.000669227950882
mg day [qnco] 0.000665924377326
progression [patf] 0.000665684425572
Currently [tmco] 0.00066443372901
Long [qlco] 0.000664099568049
Compound [qlco] 0.000662032871369
Half [qnco] 0.000658727050614
Odds Ratio [qnco] 0.000655513922862
Strong [qlco] 0.000655358816045
Initial [tmco] 0.000654883479253
Out [spco] 0.000653975575941
occurrence [ftcn] 0.000653090983008
Contrast [qlco] 0.000652242462338
Issue [fndg] 0.000651154506677
Progesterone [horm, phsu, strd] 0.000650144514215
objectives [inpr] 0.000649332565167
Event [evnt] 0.000647037113727
Comparison [acty] 0.000646865848973
R- [spco] 0.000646628936233
Status [qlco] 0.0006463935573
mediated [socb] 0.00064549260605
Surgery [bmod] 0.000642698270665
Concern [idcn] 0.000641762098594
investigated [ftcn] 0.000640389506045
Published [ocac] 0.000638172244132
Discharge [bdsu] 0.000629486663686
Syndromes, Acute Coronary [dsyn] 0.000626317101984
side effects [ftcn] 0.000625897278966
Control Group [grup] 0.000625153133857
Additional [ftcn] 0.000624438873718
Simvastatin [orch, phsu] 0.000620907305148
Proportion [qnco] 0.000617808928118
Female [fndg] 0.000617469538346
Article [inpr] 0.000617297103112
Cost [qnco] 0.000616796938336
Model [inpr] 0.000615554363887
Fasting [fndg] 0.000614816849674
Measure [qnco] 0.000613434420625
Identified [qlco] 0.000612342039688
Male [fndg] 0.000608861963439
Characteristics [qlco] 0.000606363911947
DOUBLE BLIND [resa] 0.000603551217213
Adjustment [inbe] 0.000602156962332
Mechanism [ftcn] 0.000601257043366
Progestagen [horm, phsu, strd] 0.000601020668781
Hypothesis [idcn] 0.000600438012693
Prognostic Factor [clna] 0.000600369078532
Compliance [qnco] 0.000596551253144
Recommended [idcn] 0.000595203011923
Limited [ftcn] 0.00059370040122
Phase [tmco] 0.000590466038885
Diseases [dsyn] 0.000588840554267
Administered [ftcn] 0.000588483075901
Lipid-lowering therapy [topp] 0.000588146446128
medroxyprogesterone acetate [horm, phsu, strd] 0.000587218387536
Correlated [qlco] 0.000586927788643
Glucose [bacs, carb, phsu] 0.000584876065595
Interaction [ftcn] 0.000582908864732
Diabetes Mellitus [dsyn] 0.000582232866614
Test [lbpr] 0.000581920310757
Alternative [cnce] 0.000574368714685
Severity [qlco] 0.000574225976341
Required [ftcn] 0.000572159652426
Now [tmco] 0.000570300584677
Females [fndg] 0.00057013316346
Cycle [tmco] 0.000569649113206
admitted [hlca] 0.000567539027811
Physicians [prog] 0.000567471662408
Diastolic blood pressure [clna] 0.0005665977956
Cohort [popg] 0.000565842498847
prognostic [inpr] 0.000565553615221
Life Style [socb] 0.000561752358143
Costs [qnco] 0.000559970444896
vascular [bpoc] 0.000559546906772
Lipoproteins [aapp, bacs] 0.000554600859018
Third [qnco] 0.000553811558996
Method [inpr] 0.000553321990626
Defined [cnce] 0.000549773468632
Administration [ocac] 0.000546676364384
Lipoprotein (a) [aapp, bacs] 0.000546580228463
Previous [tmco] 0.000545334280109
Assigned [ftcn] 0.000542341575758
regimens [inpr] 0.000542066768042
Delay [tmco] 0.00054088224432
Favorable [qlco] 0.000540423552638
Chemoprevention [topp] 0.000540187004728
Diagnosed [fndg] 0.000539677865241
Low Risk [fndg] 0.000538903683743
Recently [tmco] 0.000536174120785
American [popg] 0.000535136554855
Presentation [idcn] 0.000534073366314
Detection [topp] 0.000533193662558
adverse effects [ftcn] 0.000532908379479
Action [ftcn] 0.000529452309269
Single [popg] 0.000529264209348
Contribute [acty] 0.000527864434387
???lead [elii, hops] 0.000526642604211
Cardiology [bmod] 0.000525509269219
Class [inpr] 0.000524270945135
Progestogens [horm, phsu, strd] 0.000523774726288
People [popg] 0.000522879521969
Sample [sbst] 0.00052266805072
Familial hypercholesterolaemia [dsyn] 0.000520626280468
Therapies [topp] 0.000520341086306
Human [humn] 0.000520284669067
System [ftcn] 0.000519618056111
Observational Study [resa] 0.00051854512554
Five [qnco] 0.000516729588547
Start [tmco] 0.000516314039128
Small [qnco] 0.000516140905608
Assessment [hlca] 0.000514694350777
Asymptomatic [fndg] 0.00051440893375
procedures [inpr] 0.000513049792928
Very [qlco] 0.000511171746163
Hormone Replacement Therapy, Post-Menopausal [topp] 0.000509589144048
secondary [neop] 0.000508029211577
density [qnco] 0.000506916541128
Estrogen Replacement [topp] 0.000506489409428
Woman [popg] 0.000505091575011
Thrombolysis [clna] 0.000504681227072
Peak [qnco] 0.000504650278294
Ischaemic [ftcn] 0.000503618206638
Fibrinogen [aapp, bacs, phsu] 0.000501565401182
Atherogenesis [patf] 0.000500637099572
Elevated [qlco] 0.000499638370778
Stage [tmco] 0.000498045440395
mmol/L [qnco] 0.000494081513177
Initiate [idcn] 0.000493521312073
Negative [qlco] 0.000491718651736
month [tmco] 0.000490656601185
Active [ftcn] 0.000490341695836
Complex [qlco] 0.000489943396439
Fatal [qlco] 0.000487153614852
Approaches [spco] 0.000484284916186
Blood [tisu] 0.00048383655696
Coronary Disease [dsyn] 0.000483830423614
smokers [fndg] 0.000483477790097
Conjugated Equine Estrogens [horm, phsu, strd] 0.000481773881345
Link [inpr] 0.000478819176706
topic3
Estrogen [horm, phsu, strd] 0.00511664182166
Menopause [phsf] 0.00319673203336
Men [popg] 0.00318354084199
N NOS [aapp, imft] 0.00289459743993
Acute myocardial infarction [dsyn] 0.00262951437367
placebo [topp] 0.00255176428246
coronary [bpoc] 0.00252434194889
Old [tmco] 0.0024807609812
Breast Cancer [neop] 0.00246946794206
randomized [resa] 0.0023982213143
Plasma [bdsu] 0.0023749040383
Blood Pressure [orgf] 0.00235735937885
Combined [qlco] 0.00229495486046
coronary artery disease [dsyn] 0.0021065275472
Subject [grup] 0.00209944613589
Death [orgf] 0.00206325974727
Cholesterol [bacs, strd] 0.00204439267582
Heart disease [dsyn] 0.00201391227517
Profile [lbpr] 0.00200359252917
Decreased [qnco] 0.00196590154658
Oral [spco] 0.00185979937901
Estradiol [horm, phsu, strd] 0.00182031633571
Lipid [lipd] 0.00180996314561
Stroke [dsyn] 0.00178505939683
Raloxifene [orch, phsu] 0.001780046834
Benefit [qnco] 0.00175537494795
Receive [qlco] 0.00166017576191
Osteoporosis [dsyn] 0.00164980603737
Confidence Interval [qnco] 0.00164950338699
diabetic [fndg] 0.00162757968737
Non [ftcn] 0.00162754677746
Recent [tmco] 0.00159824686293
Reported [inpr] 0.0015788093931
Drug Therapy [topp] 0.0015667705033
Decrease [qlco] 0.00155542154909
Diet [food] 0.00153180042215
Myocardial Infarction [dsyn] 0.00151179281318
Benefits [qnco] 0.0014942383473
Estrogen Replacement Therapy [topp] 0.00147957766675
Change [ftcn] 0.00146420733453
findings [ftcn] 0.00145473203065
Similar [qlco] 0.00145080550395
Need [qlco] 0.00144842138892
Overall [inpr] 0.00144479401041
considered [idcn] 0.00144299193721
Incidence [qnco] 0.00144181066508
Diabetes [dsyn] 0.00142274076868
Range [qnco] 0.00141638414225
days [tmco] 0.00139473671536
symptoms [ftcn] 0.00138943636843
Current [tmco] 0.0013518520987
Improved [qlco] 0.00134154129509
mg% [qnco] 0.00133570178562
LTD [ortf] 0.00132470694896
Early [tmco] 0.0013222382808
PREVENT [phsu] 0.00131701114445
Alone [qnco] 0.00131612997584
Low Density Lipoprotein Cholesterol [bacs, strd] 0.00131382993398
Complications [patf] 0.00131071416615
Association [menp] 0.00130401496941
Large [qnco] 0.00129920862736
Total Cholesterol [lbpr] 0.00129896363176
Aged [orga] 0.00129565340004
Diagnosis [fndg] 0.00128891589978
High Risk [qlco] 0.00128837803797
Possible [qlco] 0.00128504882916
Received [qlco] 0.00126488247206
Specific [qlco] 0.00126487631763
lowering [spco] 0.00125970391605
low [qlco] 0.0012583532453
Atherosclerosis [dsyn] 0.00125736115737
Drug [phsu] 0.00125668517269
Assess [acty] 0.00125373458496
Common [qnco] 0.0012457615184
Cases [ftcn] 0.00124345910087
acute [tmco] 0.00124165349737
Measured [qlco] 0.00124098744152
Independent [idcn] 0.00120902787783
Onset [qlco] 0.00119756032775
ischaemic heart disease [dsyn] 0.00119035274418
Evaluated [ftcn] 0.00118757393969
Triglycerides [bacs, lipd] 0.00118387813381
mg dl [qnco] 0.00118140270987
Heart failure [dsyn] 0.00117948273475
median [spco] 0.00117428327799
Individual [popg] 0.00116090828286
Equal [qlco] 0.00115096999568
condition [dsyn] 0.00113751175297
Dose [qnco] 0.00112708937704
Smoking [inbe] 0.00112679075457
Lp(a) [aapp, bacs] 0.00111881105491
I- [inch] 0.00111660218874
Cholesterol, LDL [bacs, strd] 0.00111541115155
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00111482549273
Several [qnco] 0.00111228998945
Progestin [horm, phsu, strd] 0.00110905819105
Target [ftcn] 0.00110343590539
Survival [acty] 0.00109934608906
Dependent [qlco] 0.00109500934204
Low density lipoprotein [aapp, bacs, lipd] 0.00109355968541
Aspirin [orch, phsu] 0.00108148536946
Four [qnco] 0.00107785303857
Knowledge [inpr] 0.00107655628695
Percent [qnco] 0.00107246330183
Mechanisms [ftcn] 0.00107072937919
Care [acty] 0.00106095162265
Users [humn] 0.00105899249655
Events [evnt] 0.00105411646877
Available [ftcn] 0.00105261593578
Combination [qlco] 0.00105047664961
Well [qlco] 0.00104861533317
Agent [chvf] 0.00104716504448
hypertensive [fndg] 0.00104652660493
cardiovascular risk factor [dsyn] 0.00104018485417
Concentrations [menp] 0.00103550682245
Odds Ratio [qnco] 0.00103518561683
experience [menp] 0.00103090632867
Known [qlco] 0.00102788182111
Primary [qlco] 0.00102563428237
Assessed [acty] 0.00102443120136
strategies [menp] 0.00102064235663
Cancer [neop] 0.00100788817955
Cardiac [bpoc] 0.00100500544686
weeks [tmco] 0.00100442092237
Life [idcn] 0.00100295891954
Improvement [cnce] 0.00099721750018
Addition [ftcn] 0.000996748471495
Presence [topp] 0.0009921500385
setting [ftcn] 0.000988321862917
Daily [tmco] 0.00098680292087
Event [evnt] 0.000981470276539
Often [tmco] 0.000975335031838
development [phsf] 0.000970248648209
Null [qnco] 0.000967629399969
Established [qlco] 0.000964856206036
System [ftcn] 0.000961894327848
Fasting [fndg] 0.000957819963034
GIVEN [cnce] 0.000956846017469
Simvastatin [orch, phsu] 0.000956100840347
Insulin [aapp, horm, phsu] 0.000955905393019
Previous [tmco] 0.000955761171625
recommendations [idcn] 0.000953453594861
Drugs [phsu] 0.000944784063723
Progesterone [horm, phsu, strd] 0.000941991435374
Following [tmco] 0.000940753042251
Induced [ftcn] 0.000940318198065
Occur [acty] 0.000936590892058
Take [hlca] 0.000933392833257
Science [ocdi] 0.000932048277207
Estrogens [horm, phsu, strd] 0.000931477631464
Parameters [fndg] 0.000929849921297
APPEAR [qlco] 0.000928133154444
Examined [fndg] 0.000925511563181
Predictor [idcn] 0.000922351641151
Main [qlco] 0.000920861080793
radiotherapy [inpr] 0.000920829612557
Article [inpr] 0.000919185447143
intervention [hlca] 0.000916349826772
Adjusted [ftcn] 0.000901284487471
objectives [inpr] 0.00090107674875
In [qnco] 0.000899333059925
HRT [topp] 0.000898286209953
Cost Effectiveness [qnco] 0.000896100145437
Relative Risk [qnco] 0.000893448479694
Transdermal [ftcn] 0.000891107885073
Likely [qlco] 0.00088629341765
Guidelines [inpr] 0.000881383906794
mmHg [qnco] 0.000880333321198
Prevalence [qnco] 0.000880164193916
Hospital [hcro, mnob] 0.000873075316603
interventions [hlca] 0.000870803541558
practice [menp] 0.000865235392739
Affect [menp] 0.000858358541595
Currently [tmco] 0.000857066664255
Values [qlco] 0.000853334284675
Purpose [ftcn] 0.000853216497205
Clinical Trials [resa] 0.00085024526042
Needed [qlco] 0.000849270135919
Body Mass Index [diap] 0.000848046496737
Systolic blood pressure [clna] 0.000846730918532
Prognosis [hlca] 0.000845592848931
Identified [qlco] 0.000841839354355
Quality [qlco] 0.000839710851198
Reducing [qlco] 0.000836294617683
Support [medd] 0.000836225256387
Comparison [acty] 0.000830888788769
Average [qnco] 0.000822167961837
Concern [idcn] 0.000820903223397
Elderly [popg] 0.00081788365714
Information [idcn] 0.000817703574846
cardiovascular events [fndg] 0.000815755486355
society [orgt] 0.000814957894531
Secondary Prevention [topp] 0.000812458686505
History [ocdi] 0.000807239258758
hormone replacement [topp] 0.000806527964998
smokers [fndg] 0.000806386331983
Atrial Fibrillation [patf] 0.000805286798926
Prognostic Factor [clna] 0.000805114349712
Evaluation [ftcn] 0.000803829707765
Response [orga] 0.000803182565702
Morbidity [qnco] 0.000803035666566
Lipoprotein [aapp, bacs] 0.000801502959067
Sex [orgf] 0.000801000386323
Characteristics [qlco] 0.000798268567
Increasing [ftcn] 0.000797492418243
national [inpr] 0.000797069727208
C-reactive protein [aapp, imft] 0.000794215839167
Provide [acty] 0.000793515687426
Phase [tmco] 0.000791929406851
IMPACT [gngm] 0.000789477825724
Heart [bpoc] 0.000788254229118
Physicians [prog] 0.000785997539424
Medical [ftcn] 0.00078575753196
Out [spco] 0.000783463524287
Recommended [idcn] 0.000779391046346
influential [idcn] 0.000777260353605
Marker [clna] 0.000774338974005
Continuous [idcn] 0.000773727715555
Same [qlco] 0.000772561837211
Obtained [ftcn] 0.000772018798902
Literature [inpr] 0.000770317994346
side effects [ftcn] 0.000768255807614
Case [ftcn] 0.000765853457428
g% [qnco] 0.000765488678048
Young [tmco] 0.000761999946841
Report [inpr] 0.000754767354828
Conduct [inbe] 0.000751222048002
Selective Estrogen Receptor Modulators [horm, phsu] 0.000749969973668
Menopausal [phsf] 0.000747308309128
participants [popg] 0.000744399265603
Normal [qlco] 0.000737952897445
size [spco] 0.000734871211947
Fibrinogen [aapp, bacs, phsu] 0.000733405227097
Therapeutic [topp] 0.000732264073024
vascular [bpoc] 0.000732124992923
function [phsf] 0.000725153996672
Duration [tmco] 0.000723315872956
Ireland [geoa] 0.000723082458596
Favorable [qlco] 0.000722176662358
Safety [hcpp] 0.000712961112547
Risk factor [qnco] 0.000709282691721
Occurred [acty] 0.00070881733935
Life Style [socb] 0.000703861984493
Issue [fndg] 0.000702305347052
Initial [tmco] 0.000700953523651
Adults [aggp] 0.000699503235857
Persons [popg] 0.000698929562478
Replacement [topp] 0.000696183893172
Serum [bdsu] 0.000695771046119
reviewed [inpr] 0.000693426430993
Expression [topp] 0.000692934980761
Second [qnco] 0.000692637453276
Administration [ocac] 0.000689121994712
Cost [qnco] 0.000688464065519
Regimen [topp] 0.00068611801769
Progestins [horm, phsu, strd] 0.000685772974702
Future [tmco] 0.000684700406746
Relationship [qlco] 0.000680924479836
Cohort [popg] 0.000678576396929
Select [acty] 0.00067653460287
Administered [ftcn] 0.000672953138476
Make [ftcn] 0.000671917443305
Dietary [food] 0.000671041637032
Better [qlco] 0.000668429267446
Test [lbpr] 0.000666262314349
Interaction [ftcn] 0.000662279628833
Hypercholesterolaemia [dsyn] 0.000658684219609
Action [ftcn] 0.000656528505413
Recently [tmco] 0.000655260180955
Progestagen [horm, phsu, strd] 0.000654078067626
Compliance [qnco] 0.000653521956981
Type [qlco] 0.000651081098572
Additional [ftcn] 0.000642365625811
variables [qlco] 0.000633495516387
month [tmco] 0.000633369716253
Controlled [ftcn] 0.000633019074755
Lipids [lipd] 0.000631449985582
Medication [phsu] 0.00063086230905
Five [qnco] 0.00063064428004
Surgery [bmod] 0.000629200320541
Effectiveness [qlco] 0.000626989916719
Contribute [acty] 0.000624425001167
Process [bpoc] 0.000623746645154
progression [patf] 0.000623351860433
European [popg] 0.000618023816398
Small [qnco] 0.000611950052124
Seen [qlco] 0.000611671350259
Estrogen Replacement [topp] 0.000611304260333
Severe [qlco] 0.000608308700529
Mechanism [ftcn] 0.000606327024523
Lipoproteins [aapp, bacs] 0.000606011945778
???lead [elii, hops] 0.000604210239706
mg day [qnco] 0.00060319023508
lack [qlco] 0.000602488679486
Diastolic blood pressure [clna] 0.000601837094493
Died [orgf] 0.000599880046043
Female [fndg] 0.000598414525012
Endothelial [tisu] 0.000598147864821
Play [dora] 0.000597695667157
confirmed [qlco] 0.000596173230258
Exercise [dora] 0.000595732296313
Ratio [qnco] 0.000593719017094
Hormone [horm] 0.000593406086094
Assigned [ftcn] 0.000592671658431
Severity [qlco] 0.000591424490012
Seven [qnco] 0.000591270717698
Relative [famg] 0.000591255435827
Method [inpr] 0.000589568089716
Approach [spco] 0.000589058519354
Part [spco] 0.000588860070536
Past [tmco] 0.000587800796012
Concentration [menp] 0.00058692880677
Treatments [topp] 0.000586368708398
Beta-Blockers [phsu] 0.00058613566863
Few [qnco] 0.000585814968399
H+ [elii] 0.000582601034531
Thrombolysis [clna] 0.000581560862259
.BETA.-Carotene [orch, phsu, vita] 0.000581102906342
mmol/L [qnco] 0.000580096744359
Obesity [dsyn] 0.000580049417357
Various [irda] 0.000579767501092
Model [inpr] 0.000579725157623
Females [fndg] 0.000579369320122
Central [spco] 0.00057778513902
Address [inpr] 0.000575286840397
Risks [qlco] 0.00057320695135
Primary Prevention [topp] 0.00057297134604
Proportion [qnco] 0.000572356319476
Class [inpr] 0.000570290289374
Conjugated Equine Estrogens [horm, phsu, strd] 0.000569072034619
atorvastatin [orch, phsu] 0.00056846362483
Breast [bpoc] 0.000568140631419
Thrombolytic Therapy [topp] 0.000563929074944
mediated [socb] 0.000563683507663
Males [fndg] 0.000558763196275
Complex [qlco] 0.000557080769139
Adjustment [inbe] 0.000556969118275
prospective [resa] 0.000556345563784
Standard [qlco] 0.000555050199501
Insulin Sensitivity [patf] 0.000553367654439
Lipid-lowering therapy [topp] 0.000551933378851
Frequent [tmco] 0.000550932503794
Male [fndg] 0.000550694818002
Extent [spco] 0.000549811189039
Compound [qlco] 0.000548156997137
Children [aggp] 0.000547814196372
Documented [hlca] 0.000545739281999
Measure [qnco] 0.000545372524976
procedures [inpr] 0.000545245912381
Elevated [qlco] 0.000544844101913
Detection [topp] 0.000544336265808
weight [orga] 0.000543297313294
Long [qlco] 0.000540374902394
Plus [qlco] 0.000538804380339
Tamoxifen [orch, phsu] 0.000538748313178
Approaches [spco] 0.000538136083846
Post-Menopause [orgf] 0.000537841465742
ACT [topp] 0.000535234402348
Program [cnce] 0.000534111258043
regimens [inpr] 0.000533696983838
Contrast [qlco] 0.000532865187879
Human [humn] 0.00053261697905
Now [tmco] 0.00053230479946
Limited [ftcn] 0.00052936498979
Glucose [bacs, carb, phsu] 0.000528336616257
formation [biof] 0.000527316734857
Platelet [cell] 0.00052324596901
Late [tmco] 0.000522346136047
distribution [idcn] 0.000522021290451
Status [qlco] 0.000521949272631
Venous Thromboembolism [patf] 0.000520620138017
prognostic [inpr] 0.000519996001942
Analyzed [resa] 0.000519725866079
Estimated [qnco] 0.000518508211894
Never [tmco] 0.000517744051633
Half [qnco] 0.000517287191969
Compare [acty] 0.000515799768013
Assessment [hlca] 0.000515115917835
Diseases [dsyn] 0.000514032499827
United States [geoa] 0.000513401826956
Supplementation [topp] 0.000513121910964
reductions [npop] 0.000512369611973
Sample [sbst] 0.000510679372823
Bleeding [patf] 0.000510590892607
R- [spco] 0.000509805793181
Woman [popg] 0.000509322609866
American [popg] 0.000508521579062
Conjugated estrogen [horm, phsu, strd] 0.000508155657458
Formulation [resa] 0.000506565185033
TREAT [ftcn] 0.000506465403389
Physical activity [dora] 0.000506393483105
Presented [idcn] 0.00050549183932
Community [geoa] 0.000505130699588
Fatal [qlco] 0.000505024278146
Myocardial [spco] 0.000504182933437
Multiple [qnco] 0.00050199207235
activity [dora] 0.000500231120242
investigated [ftcn] 0.000500151416305
Expected [idcn] 0.000499425927805
density [qnco] 0.000497676630143
topic4
Estrogen [horm, phsu, strd] 0.00607792435251
Men [popg] 0.0036267212964
Menopause [phsf] 0.0031842559372
Acute myocardial infarction [dsyn] 0.00297265635487
N NOS [aapp, imft] 0.00286837385663
Blood Pressure [orgf] 0.00273064868793
Old [tmco] 0.00254873062216
coronary [bpoc] 0.00250939790125
Receive [qlco] 0.0025002576698
Lipid [lipd] 0.00240117700935
placebo [topp] 0.00226372516445
Drug [phsu] 0.00217947640324
Benefit [qnco] 0.00216250790173
Myocardial Infarction [dsyn] 0.00204522445246
Stroke [dsyn] 0.00201474358733
Subject [grup] 0.00200482236453
Early [tmco] 0.00198408321264
Incidence [qnco] 0.00196554852408
Combined [qlco] 0.00195564203856
Decrease [qlco] 0.00194095675796
Breast Cancer [neop] 0.00192752887569
coronary artery disease [dsyn] 0.00187442957927
Similar [qlco] 0.0018731512193
Raloxifene [orch, phsu] 0.00186167762149
Plasma [bdsu] 0.00181188487199
High Risk [qlco] 0.00178098786091
Oral [spco] 0.00177721027351
Received [qlco] 0.00172685619281
randomized [resa] 0.00171371820223
Drug Therapy [topp] 0.00168098675256
Survival [acty] 0.00168004503411
mg% [qnco] 0.00167913725286
Cases [ftcn] 0.00167278299755
Current [tmco] 0.00167172823666
Common [qnco] 0.00164393773784
Confidence Interval [qnco] 0.00163709330907
PREVENT [phsu] 0.0016187078813
Non [ftcn] 0.0015917448093
Diabetes [dsyn] 0.00158927514516
Recent [tmco] 0.00156696806805
Osteoporosis [dsyn] 0.00149495992587
Aged [orga] 0.00148013757969
Estradiol [horm, phsu, strd] 0.0014749614077
Total Cholesterol [lbpr] 0.00144758609882
intervention [hlca] 0.00143826853129
Reported [inpr] 0.0014345652224
Likely [qlco] 0.00143416262293
low [qlco] 0.00142729386881
Decreased [qnco] 0.00142384452872
Alone [qnco] 0.00141836959168
findings [ftcn] 0.00141796710687
Diet [food] 0.00139090406796
Death [orgf] 0.001377697094
Evaluated [ftcn] 0.00136779169677
Science [ocdi] 0.00136366500344
Prevalence [qnco] 0.00135234088125
symptoms [ftcn] 0.00134641798379
Low density lipoprotein [aapp, bacs, lipd] 0.00134139407138
Estrogens [horm, phsu, strd] 0.00133894822421
Users [humn] 0.00133199240993
Profile [lbpr] 0.00132868087805
Smoking [inbe] 0.0013156599297
days [tmco] 0.00131411738578
Measured [qlco] 0.00130002884775
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00128753015925
Available [ftcn] 0.00128521078533
Equal [qlco] 0.00127865051977
Overall [inpr] 0.00127839439952
Individual [popg] 0.00127341950795
Cholesterol [bacs, strd] 0.00127289822874
Simvastatin [orch, phsu] 0.00126851707739
Target [ftcn] 0.00126438873377
Change [ftcn] 0.00124560432983
development [phsf] 0.00123563379813
Insulin [aapp, horm, phsu] 0.00123497167564
mg dl [qnco] 0.00123378064072
Percent [qnco] 0.00123199170874
diabetic [fndg] 0.00121197320939
Hypercholesterolaemia [dsyn] 0.00120341724674
ischaemic heart disease [dsyn] 0.00119486174399
Agent [chvf] 0.00119397496887
Null [qnco] 0.00119048960597
Cancer [neop] 0.00118574131838
Possible [qlco] 0.00118320558656
Large [qnco] 0.00118027730557
Estrogen Replacement Therapy [topp] 0.00117676815153
APPEAR [qlco] 0.0011681267341
Provide [acty] 0.00116749518315
Elderly [popg] 0.00116688272236
Combination [qlco] 0.00116397710395
Parameters [fndg] 0.00115568706609
Addition [ftcn] 0.00115358793441
Cardiac [bpoc] 0.00115015205563
Specific [qlco] 0.00114857998512
I- [inch] 0.00114268560106
Complications [patf] 0.00112823009589
Daily [tmco] 0.00112363957849
median [spco] 0.00111653528809
Response [orga] 0.00111587564896
Need [qlco] 0.00110791643081
Range [qnco] 0.00110204207194
Progestin [horm, phsu, strd] 0.0010944158116
Assess [acty] 0.00109314400795
Drugs [phsu] 0.00108445996592
Menopausal [phsf] 0.00108261272421
mmHg [qnco] 0.00107755260358
Relative Risk [qnco] 0.00107497102926
GIVEN [cnce] 0.00106545213175
Triglycerides [bacs, lipd] 0.00106149873819
Occur [acty] 0.00106147523785
Several [qnco] 0.00105348826513
Odds Ratio [qnco] 0.0010500257727
Association [menp] 0.00104846037126
Lp(a) [aapp, bacs] 0.00104660460863
Induced [ftcn] 0.0010451069034
strategies [menp] 0.00104489439413
national [inpr] 0.00104073332281
Hospital [hcro, mnob] 0.0010372701589
Therapeutic [topp] 0.00103474269262
Obesity [dsyn] 0.00103317070181
Dose [qnco] 0.0010225265175
Identified [qlco] 0.00100858781762
Presence [topp] 0.00100500051271
setting [ftcn] 0.0010049802791
Benefits [qnco] 0.000994609242577
Prognosis [hlca] 0.000993833333614
Guidelines [inpr] 0.000985389435816
Information [idcn] 0.000974823282598
society [orgt] 0.000968792877536
acute [tmco] 0.000966041835932
Previous [tmco] 0.000964777588524
Conduct [inbe] 0.000962875663075
Independent [idcn] 0.000962579581681
Four [qnco] 0.000962310470035
LTD [ortf] 0.0009582484672
condition [dsyn] 0.000956892888538
Test [lbpr] 0.000950167983719
weeks [tmco] 0.000948342887502
Atrial Fibrillation [patf] 0.000943888141308
cardiovascular risk factor [dsyn] 0.000942035130315
IMPACT [gngm] 0.000941296391743
Values [qlco] 0.000938575139687
Take [hlca] 0.00093828547827
considered [idcn] 0.000935745048428
Improved [qlco] 0.00093239139808
Atherosclerosis [dsyn] 0.000930354938381
Examined [fndg] 0.000930236664626
Predictor [idcn] 0.000930176118754
Cohort [popg] 0.000918657165617
Heart disease [dsyn] 0.000918218042276
History [ocdi] 0.000916302957186
Improvement [cnce] 0.000906757194924
participants [popg] 0.000905574535672
Currently [tmco] 0.000903769699757
Primary [qlco] 0.000901238395509
Mechanisms [ftcn] 0.00089982311296
Known [qlco] 0.000898272332824
Clinical Trials [resa] 0.000891214765236
experience [menp] 0.00089006023093
Well [qlco] 0.000886641957094
Main [qlco] 0.000884956273397
Concentrations [menp] 0.000883889284085
Children [aggp] 0.000873860077098
Body Mass Index [diap] 0.000869958090747
Onset [qlco] 0.000867345643341
Affect [menp] 0.000866572639904
investigated [ftcn] 0.000850876950084
Additional [ftcn] 0.000849822922478
C-reactive protein [aapp, imft] 0.000848385435436
Events [evnt] 0.000848129839019
Serum [bdsu] 0.000846608740756
Case [ftcn] 0.000838418544945
Established [qlco] 0.000836729065398
practice [menp] 0.00083218533918
Lipoprotein [aapp, bacs] 0.000831730966714
size [spco] 0.000827672876056
Purpose [ftcn] 0.000825704714329
Increasing [ftcn] 0.000824522650799
Progestagen [horm, phsu, strd] 0.000824496956042
influential [idcn] 0.000822945033121
Safety [hcpp] 0.000819789391255
Reducing [qlco] 0.000819339586944
radiotherapy [inpr] 0.000818580013904
Contribute [acty] 0.000815503443605
Relationship [qlco] 0.000814571521816
Late [tmco] 0.000811375327135
System [ftcn] 0.000810472896096
interventions [hlca] 0.000810043188641
Life [idcn] 0.0008085256624
Sex [orgf] 0.000808462301859
Care [acty] 0.000803687392818
Needed [qlco] 0.000802777084022
Diabetes Mellitus [dsyn] 0.000800904175596
Morbidity [qnco] 0.00079965635423
Phase [tmco] 0.000799057240052
Report [inpr] 0.000798373100141
Lipids [lipd] 0.000797666145677
activity [dora] 0.000795852287359
Compare [acty] 0.000794646912091
Assessed [acty] 0.000790810546349
Replacement [topp] 0.000790229549564
lowering [spco] 0.000787444959857
Heart failure [dsyn] 0.000783482570572
Progesterone [horm, phsu, strd] 0.000782168650765
Evaluation [ftcn] 0.000779991959285
R- [spco] 0.000779346952467
Diagnosis [fndg] 0.00077344483043
Strong [qlco] 0.000772855104106
Marker [clna] 0.000772643170207
Aspirin [orch, phsu] 0.000771135751993
Secondary Prevention [topp] 0.000767056142851
Ratio [qnco] 0.000766791847768
United States [geoa] 0.000763633200245
Fatal [qlco] 0.000762222547291
Diastolic blood pressure [clna] 0.000752037930329
Ireland [geoa] 0.000750067019906
Heart [bpoc] 0.000747914915174
Model [inpr] 0.000739197495363
hypertensive [fndg] 0.000736732361526
Make [ftcn] 0.000734601904154
Event [evnt] 0.000733017630195
Concern [idcn] 0.000731492823521
Article [inpr] 0.000728581048104
Cholesterol, LDL [bacs, strd] 0.000727742179308
Average [qnco] 0.000727690359591
Process [bpoc] 0.00072624327442
objectives [inpr] 0.000725060645113
variables [qlco] 0.000720388223508
Characteristics [qlco] 0.000715583750254
Following [tmco] 0.000714548762606
HRT [topp] 0.000707442341758
Medical [ftcn] 0.000706507479287
function [phsf] 0.00070367461739
Knowledge [inpr] 0.000701674569686
month [tmco] 0.000701467024702
Ischaemic [ftcn] 0.000694144255572
Initial [tmco] 0.000693080795324
tibolone [phsu, strd] 0.000691075802714
Transdermal [ftcn] 0.000689333047102
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000686237858328
Appropriate [qlco] 0.000685620446867
Support [medd] 0.000681599148225
Normal [qlco] 0.000680822241829
atorvastatin [orch, phsu] 0.00067997572865
Often [tmco] 0.000679588631472
Compliance [qnco] 0.000677778082786
Prognostic Factor [clna] 0.00067550892601
Effectiveness [qlco] 0.000674963760991
Duration [tmco] 0.000669553148308
reviewed [inpr] 0.000668309281857
Surgery [bmod] 0.000667928530926
Recently [tmco] 0.00066669953276
Estimated [qnco] 0.000663803894547
Negative [qlco] 0.000662442482982
Risks [qlco] 0.000662156898724
vascular [bpoc] 0.000659622446328
Adults [aggp] 0.000656160734395
smokers [fndg] 0.000655938232608
Published [ocac] 0.000654003584155
Comparison [acty] 0.000651640654077
Equine [mamm] 0.000649781012884
Quality [qlco] 0.000647994889506
Out [spco] 0.000642791703146
Mechanism [ftcn] 0.000637870135418
Glucose [bacs, carb, phsu] 0.000637471340796
mediated [socb] 0.000637012139077
Relative [famg] 0.000636335597491
Fibrinogen [aapp, bacs, phsu] 0.000635049069601
Select [acty] 0.000634795906125
Exercise [dora] 0.00063373886832
Controlled [ftcn] 0.000632747480797
Focus [spco] 0.000631231275712
Systolic blood pressure [clna] 0.000626407868008
Cholesterol, HDL [bacs, lipd] 0.000626252129845
Play [dora] 0.000625142072443
recommendations [idcn] 0.0006232740612
Single [popg] 0.000622501800574
Cost [qnco] 0.000621741916507
Severity [qlco] 0.000619988306364
Administered [ftcn] 0.000618122676908
Risk factor [qnco] 0.000616272795651
Approach [spco] 0.000615997172789
Young [tmco] 0.000614875912044
Complex [qlco] 0.000613535464895
mg day [qnco] 0.000613508391369
lack [qlco] 0.000613226172374
DOUBLE BLIND [resa] 0.000608767336513
Lipoproteins [aapp, bacs] 0.000608162047948
Seen [qlco] 0.000606518297701
Favorable [qlco] 0.000604768213666
Thrombolytic Therapy [topp] 0.000604741030925
Dependent [qlco] 0.000603933593642
Continuous [idcn] 0.000603440183017
side effects [ftcn] 0.000603369678996
cardiovascular events [fndg] 0.000603276495631
Cost Effectiveness [qnco] 0.000602384909268
g% [qnco] 0.000601979032529
European [popg] 0.000601068115037
Part [spco] 0.00059971087447
.BETA.-Carotene [orch, phsu, vita] 0.000599392615841
Endothelial [tisu] 0.000596391012729
Past [tmco] 0.000595487968355
Tamoxifen [orch, phsu] 0.000594258465981
Physical activity [dora] 0.000592320396528
Selective Estrogen Receptor Modulators [horm, phsu] 0.000590673619309
adverse effects [ftcn] 0.000590653565145
Adjusted [ftcn] 0.000589285323708
In [qnco] 0.000589176956576
Physicians [prog] 0.000589001779824
Consecutive [qlco] 0.000586047283311
Better [qlco] 0.00058588160744
mmol/L [qnco] 0.000585326718422
Same [qlco] 0.000584991025658
hormone replacement [topp] 0.000582287503707
Breast [bpoc] 0.000581861974262
Male [fndg] 0.000580214274604
Long [qlco] 0.000578217778869
Diseases [dsyn] 0.000577700726568
Estrogen Replacement [topp] 0.000577660299458
Dietary [food] 0.000577439101191
Observational Study [resa] 0.000577138394627
Statins [orch, phsu] 0.00057675900138
Syndromes, Acute Coronary [dsyn] 0.000573238056193
Indicated [fndg] 0.000570254678922
Administration [ocac] 0.000568293930702
Sample [sbst] 0.000566202883082
Literature [inpr] 0.000564742301066
Various [irda] 0.000564629468009
Area [geoa] 0.00056434433183
Type [qlco] 0.000561965915027
Interaction [ftcn] 0.000561462478027
Infarction [patf] 0.000559976120602
Understanding [menp] 0.000559565418492
Insulin Sensitivity [patf] 0.000559526367881
Obtained [ftcn] 0.000558741712735
Few [qnco] 0.000557040796927
Stage [tmco] 0.000556285956475
Expression [topp] 0.000556252018761
progression [patf] 0.000554526706846
Detection [topp] 0.00055396540444
Concentration [menp] 0.000551431411496
Delay [tmco] 0.000549761701906
Now [tmco] 0.000549456652036
Half [qnco] 0.000549117762883
Plus [qlco] 0.000540436503345
Method [inpr] 0.000538496152454
Low Risk [fndg] 0.000538434169493
Five [qnco] 0.000536313853836
Never [tmco] 0.00053615425628
Initiate [idcn] 0.000533108667576
Recommended [idcn] 0.000530632695486
confirmed [qlco] 0.000529237851157
reductions [npop] 0.000526544244707
Human [humn] 0.000526288614397
Presented [idcn] 0.000526102035322
Expected [idcn] 0.000525285785411
Start [tmco] 0.000524773075544
Future [tmco] 0.00052103886221
Hormone [horm] 0.000520914510506
Required [ftcn] 0.000520035228262
Fasting [fndg] 0.000519703595233
Progestins [horm, phsu, strd] 0.000519207193304
deaths [orgf] 0.000515778701501
Regimen [topp] 0.000513695953076
Second [qnco] 0.000513206299316
Medications [phsu] 0.000512481518188
Third [qnco] 0.000512086812998
admitted [hlca] 0.000511766090786
H+ [elii] 0.00051176182097
Persons [popg] 0.00051155626756
Approaches [spco] 0.000511207331185
Compound [qlco] 0.000510163938107
Extent [spco] 0.000509225609931
Life Style [socb] 0.000507848190004
Analyzed [resa] 0.00050700467325
Standard [qlco] 0.000506486310569
Adjustment [inbe] 0.000506406548819
regimens [inpr] 0.000506340988322
Age-Years [tmco] 0.000504447334194
prescribed [hlca] 0.000503252929631
properties [qlco] 0.000499122252108
Venous Thromboembolism [patf] 0.000497673245548
American [popg] 0.000496549000368
Female [fndg] 0.000495740093568
Control Group [grup] 0.000495737537118
Medication [phsu] 0.000495418479674
Little NOS [cgab, dsyn] 0.000495324522808
heart rate [clna] 0.000494941800385
Assigned [ftcn] 0.000493301389833
Cardiology [bmod] 0.000493286540107
Class [inpr] 0.000492576240301
Leading [tmco] 0.000489455932825
Hyperlipidaemia [dsyn] 0.000489021628797
Ii [aapp] 0.00048809488902
majority [socb] 0.000487275869276
Conjugated estrogen [horm, phsu, strd] 0.000486595435907
Lipid-lowering therapy [topp] 0.000486171453978
Beta-Blockers [phsu] 0.000483345395541
End [spco] 0.000482334448749
Documented [hlca] 0.000482050856789
topic5
Estrogen [horm, phsu, strd] 0.00495441730689
Menopause [phsf] 0.00332807470886
Breast Cancer [neop] 0.00314094248665
Plasma [bdsu] 0.0029255281544
Acute myocardial infarction [dsyn] 0.00292150052489
Men [popg] 0.00273236569539
Combined [qlco] 0.00232999106087
coronary [bpoc] 0.0023244249343
N NOS [aapp, imft] 0.00230191663658
Subject [grup] 0.00228946668725
Incidence [qnco] 0.00221428959452
Receive [qlco] 0.0021981624436
Decreased [qnco] 0.00218123878211
Lipid [lipd] 0.00216491299231
Received [qlco] 0.00215031010431
Stroke [dsyn] 0.00213428563431
Death [orgf] 0.00208567876354
Early [tmco] 0.00204161174189
Cholesterol [bacs, strd] 0.00200010990093
coronary artery disease [dsyn] 0.00196497663672
Myocardial Infarction [dsyn] 0.0019491582147
Confidence Interval [qnco] 0.00190715865892
Drug Therapy [topp] 0.00184427613433
Non [ftcn] 0.00184226308678
placebo [topp] 0.00180538514026
Old [tmco] 0.00180431641868
Common [qnco] 0.00179801075942
Diabetes [dsyn] 0.0017670886025
Current [tmco] 0.00176609553405
PREVENT [phsu] 0.00175316679065
Drug [phsu] 0.00175252918161
Similar [qlco] 0.00173156329927
Decrease [qlco] 0.00171094394247
Osteoporosis [dsyn] 0.00169563004743
Measured [qlco] 0.00166704888794
Individual [popg] 0.00161978814126
Estradiol [horm, phsu, strd] 0.00160112306274
symptoms [ftcn] 0.00157777303539
Reported [inpr] 0.00153979819038
mg% [qnco] 0.00153615793789
Benefit [qnco] 0.00153240473041
Blood Pressure [orgf] 0.00151281830296
diabetic [fndg] 0.00149388111422
randomized [resa] 0.00147701667285
Raloxifene [orch, phsu] 0.00145972093964
Improved [qlco] 0.00145584445842
Assess [acty] 0.00145528150987
Diet [food] 0.00144933918092
Combination [qlco] 0.00144919449997
Available [ftcn] 0.00144706550054
Well [qlco] 0.0013977359875
Take [hlca] 0.00139034711489
Users [humn] 0.00137381644586
Survival [acty] 0.00137369078967
Profile [lbpr] 0.00135800239471
Likely [qlco] 0.00135681053326
Association [menp] 0.00135496247747
Oral [spco] 0.0013497555388
Aged [orga] 0.00132465284485
Cases [ftcn] 0.00131694828173
low [qlco] 0.00131454014022
Information [idcn] 0.0013135256231
Overall [inpr] 0.00127571799482
acute [tmco] 0.00127377001614
Induced [ftcn] 0.0012643429224
Equal [qlco] 0.00125837883611
Low density lipoprotein [aapp, bacs, lipd] 0.00124931639985
median [spco] 0.0012491642675
Change [ftcn] 0.00124656173412
Dose [qnco] 0.00124473767138
Independent [idcn] 0.00124012438296
Insulin [aapp, horm, phsu] 0.0012352504222
Recent [tmco] 0.00122757531243
Large [qnco] 0.00122381376814
Drugs [phsu] 0.00120950345339
Range [qnco] 0.00120409332933
Possible [qlco] 0.00120393101981
Cancer [neop] 0.00119838633277
Known [qlco] 0.00118929549874
Agent [chvf] 0.00118123713049
Events [evnt] 0.001173216252
days [tmco] 0.00117162038757
intervention [hlca] 0.00117112718668
Progestin [horm, phsu, strd] 0.00116395571292
considered [idcn] 0.00115931012349
Complications [patf] 0.00112611997185
Addition [ftcn] 0.0011188003734
Heart disease [dsyn] 0.00111340552072
Alone [qnco] 0.00109668101583
Diagnosis [fndg] 0.00109595349916
Cardiac [bpoc] 0.00109114980896
High Risk [qlco] 0.00109105724828
Odds Ratio [qnco] 0.00108743913193
Estrogen Replacement Therapy [topp] 0.00108099525092
Obesity [dsyn] 0.0010708178539
Benefits [qnco] 0.00106366550779
Daily [tmco] 0.00106132718463
Four [qnco] 0.00106120381481
Improvement [cnce] 0.00105853006899
experience [menp] 0.00104698948076
Heart [bpoc] 0.00104098800382
society [orgt] 0.00103724226355
Need [qlco] 0.0010356346673
Smoking [inbe] 0.00103441355249
Care [acty] 0.00101756150476
Prevalence [qnco] 0.0010149134191
Simvastatin [orch, phsu] 0.00101084285169
Hospital [hcro, mnob] 0.00100864020759
High Density Lipoprotein Cholesterol [bacs, lipd] 0.0010079550189
Serum [bdsu] 0.00100109926553
Percent [qnco] 0.000997347669012
History [ocdi] 0.000996499177991
Evaluated [ftcn] 0.000992796751328
APPEAR [qlco] 0.000992314950503
Atherosclerosis [dsyn] 0.000991545158075
development [phsf] 0.000985989568838
Science [ocdi] 0.000984710869313
Prognosis [hlca] 0.000980249670028
Parameters [fndg] 0.000979578376867
Several [qnco] 0.000976352286948
Secondary Prevention [topp] 0.000971073400915
Low Density Lipoprotein Cholesterol [bacs, strd] 0.00096664266794
setting [ftcn] 0.000966166147915
Following [tmco] 0.000960656320739
hypertensive [fndg] 0.000960054484459
Prognostic Factor [clna] 0.000959480503462
Null [qnco] 0.000958385021803
Increasing [ftcn] 0.000953641081746
Report [inpr] 0.000953540475934
Specific [qlco] 0.000946135580452
Relationship [qlco] 0.00094479844405
Selective Estrogen Receptor Modulators [horm, phsu] 0.00094368765329
Triglycerides [bacs, lipd] 0.000942202377707
Predictor [idcn] 0.000941856483191
Cholesterol, LDL [bacs, strd] 0.000938345118816
Currently [tmco] 0.0009353413554
Atrial Fibrillation [patf] 0.000934535972644
Concentrations [menp] 0.000929765106952
mg dl [qnco] 0.000917554163605
Assessed [acty] 0.000913985728553
Provide [acty] 0.000910048204476
strategies [menp] 0.000909903632119
mmHg [qnco] 0.000909458903568
Various [irda] 0.00090825916433
recommendations [idcn] 0.000907411595313
condition [dsyn] 0.000896327443529
Duration [tmco] 0.000891476516462
IMPACT [gngm] 0.000887490350197
Affect [menp] 0.000887145740026
Diseases [dsyn] 0.000880532679228
Safety [hcpp] 0.000880010766245
Target [ftcn] 0.000875834575129
HRT [topp] 0.000867847239257
Knowledge [inpr] 0.000866500105003
practice [menp] 0.000866311153037
Conduct [inbe] 0.000864540396681
Clinical Trials [resa] 0.000857979122759
Needed [qlco] 0.000855689716966
Purpose [ftcn] 0.000849992347398
Select [acty] 0.000849099756667
Medical [ftcn] 0.000847612968929
Obtained [ftcn] 0.000845348840385
Onset [qlco] 0.000842655453889
Primary [qlco] 0.000840336291897
findings [ftcn] 0.000837888945806
Aspirin [orch, phsu] 0.000836986237436
Issue [fndg] 0.000833355063128
Cost [qnco] 0.000830626890423
Occur [acty] 0.000828839045085
Interaction [ftcn] 0.000828288117426
interventions [hlca] 0.000826417278623
Evaluation [ftcn] 0.000823542796538
Sex [orgf] 0.000822578998268
LTD [ortf] 0.000820933718165
Action [ftcn] 0.000814764203434
Relative Risk [qnco] 0.000813484937143
influential [idcn] 0.000813381141871
Dependent [qlco] 0.000812143368686
Heart failure [dsyn] 0.000811971026099
Total Cholesterol [lbpr] 0.000804971719133
Article [inpr] 0.000804401102404
Main [qlco] 0.000802950699346
Test [lbpr] 0.000799310710224
Mechanisms [ftcn] 0.000797351670713
Late [tmco] 0.0007964494761
Often [tmco] 0.000794309309554
function [phsf] 0.000791919301917
Cost Effectiveness [qnco] 0.000791371063445
Values [qlco] 0.000790721239491
Fasting [fndg] 0.000790655922537
Surgery [bmod] 0.000789423304787
cardiovascular risk factor [dsyn] 0.000789174023942
Estrogens [horm, phsu, strd] 0.000788437406176
I- [inch] 0.000787638589922
Examined [fndg] 0.000787545365243
Administration [ocac] 0.000786414718154
Identified [qlco] 0.000784338869435
Transdermal [ftcn] 0.00078415076296
Elderly [popg] 0.000782376568617
Strong [qlco] 0.000781958016897
Characteristics [qlco] 0.000779958796198
Fibrinogen [aapp, bacs, phsu] 0.000779851596996
month [tmco] 0.000779079702481
national [inpr] 0.00077817692055
Published [ocac] 0.000775950135484
Five [qnco] 0.00077468589632
Model [inpr] 0.000771332966313
Replacement [topp] 0.000766822659164
System [ftcn] 0.00076677293885
Severe [qlco] 0.000763911845187
Guidelines [inpr] 0.000763316667408
Previous [tmco] 0.000763220193888
mg day [qnco] 0.000762438186963
Cohort [popg] 0.00076035911098
Comparison [acty] 0.000756129467521
Effectiveness [qlco] 0.000754452662511
Continuous [idcn] 0.000751578093161
GIVEN [cnce] 0.00075155119104
Compound [qlco] 0.000748154239499
Physical activity [dora] 0.000740888703416
Response [orga] 0.000740313087277
Diabetes Mellitus [dsyn] 0.000739860481119
Morbidity [qnco] 0.000739198124308
Average [qnco] 0.000736971039405
Established [qlco] 0.000735646920495
Compliance [qnco] 0.000734223623129
Better [qlco] 0.000734149323023
Marker [clna] 0.000732462105802
regimens [inpr] 0.000725796234144
g% [qnco] 0.000724860067837
Lipoprotein [aapp, bacs] 0.00071875405935
Regimen [topp] 0.000717553189258
ischaemic heart disease [dsyn] 0.000708543633641
Sample [sbst] 0.000706727202713
Past [tmco] 0.000706289948611
C-reactive protein [aapp, imft] 0.000699015801865
Fatal [qlco] 0.000695311133783
Second [qnco] 0.000694278525753
Complex [qlco] 0.000694057530098
Presence [topp] 0.000691104356789
.BETA.-Carotene [orch, phsu, vita] 0.000690130520874
Relative [famg] 0.000689163753644
Support [medd] 0.000688771926323
Life [idcn] 0.000688046752985
Administered [ftcn] 0.000687567424844
lowering [spco] 0.000685828183686
size [spco] 0.000685036584695
Infarction [patf] 0.000684781820427
Initiate [idcn] 0.000682749605982
Few [qnco] 0.000681730845309
hormone replacement [topp] 0.000680196594059
radiotherapy [inpr] 0.000678742015995
participants [popg] 0.000676185619271
Lp(a) [aapp, bacs] 0.000671466174857
Children [aggp] 0.000669766975418
Same [qlco] 0.000668320084368
weeks [tmco] 0.000667996311586
United States [geoa] 0.000667193996222
Concern [idcn] 0.000666573644314
Congestive heart failure [dsyn] 0.000665683918804
smokers [fndg] 0.00066243767393
Therapeutic [topp] 0.000661729345187
prognostic [inpr] 0.000660680085528
Body Mass Index [diap] 0.00065977844123
Cardiology [bmod] 0.00065652400967
cardiovascular events [fndg] 0.000654905173759
Lipoproteins [aapp, bacs] 0.000653605088828
Part [spco] 0.000651821615652
Contribute [acty] 0.000647875812951
Estrogen Replacement [topp] 0.000647647721673
occurrence [ftcn] 0.000647443363657
Hormone [horm] 0.000646775939538
mmol/L [qnco] 0.000646518999674
Additional [ftcn] 0.000646161741064
Adjusted [ftcn] 0.000643548620865
Recently [tmco] 0.000642585627025
Start [tmco] 0.000642414060521
Ireland [geoa] 0.000641983848999
Treatments [topp] 0.000640329040091
side effects [ftcn] 0.000640251636749
progression [patf] 0.000639054989994
Endothelial [tisu] 0.000637597509974
Controlled [ftcn] 0.000637155875625
Exercise [dora] 0.000636054865834
Favorable [qlco] 0.000635781747768
Literature [inpr] 0.000635384120501
Diastolic blood pressure [clna] 0.000633296476172
Concentration [menp] 0.000632179476062
Case [ftcn] 0.000631182704038
Phase [tmco] 0.000629183810765
variables [qlco] 0.0006271626542
Elevated [qlco] 0.000624425361025
Plus [qlco] 0.00062356844659
Future [tmco] 0.000623462101535
Event [evnt] 0.000620586234172
Type [qlco] 0.000617717523306
Method [inpr] 0.000617334821044
Point [qnco] 0.00061611998538
investigate [ftcn] 0.000615728600553
Life Style [socb] 0.000613478758312
Quality [qlco] 0.000613454621438
reviewed [inpr] 0.000613159213885
Reducing [qlco] 0.000612706606369
Now [tmco] 0.000611036051498
Menopausal [phsf] 0.000608299746762
Out [spco] 0.00060565924969
lack [qlco] 0.000604289765819
Measure [qnco] 0.000600782410277
Beta-Blockers [phsu] 0.000600682944031
Estimated [qnco] 0.000600608652234
Central [spco] 0.000600370659935
Initial [tmco] 0.000599537391391
Recommended [idcn] 0.00059924371871
Seen [qlco] 0.000598844577662
Serious [qlco] 0.00059811459171
Make [ftcn] 0.000595663754427
Limited [ftcn] 0.000595174680395
Adjustment [inbe] 0.000593730734504
tibolone [phsu, strd] 0.000589392936906
Tamoxifen [orch, phsu] 0.000589175540065
Radiation [npop] 0.000586401017265
Goal [inpr] 0.000586139750324
Assigned [ftcn] 0.000585430820957
In [qnco] 0.000583152868944
Ratio [qnco] 0.000582447825994
Approach [spco] 0.000582008286375
Adults [aggp] 0.000581637073929
Insulin Sensitivity [patf] 0.000581195687157
Correlated [qlco] 0.000580991252213
Occurred [acty] 0.000580799961131
Diagnosed [fndg] 0.000579320913062
Negative [qlco] 0.000578504111873
Loss [qnco] 0.000576659832964
Class [inpr] 0.000574942510548
Progestagen [horm, phsu, strd] 0.000574216238697
Dietary [food] 0.000573439329267
Human [humn] 0.000572618096171
Syndromes, Acute Coronary [dsyn] 0.000567096857576
Mechanism [ftcn] 0.000565560722454
Ii [aapp] 0.000565498835829
Breast [bpoc] 0.00056430380806
Consecutive [qlco] 0.000562579509885
Glucose [bacs, carb, phsu] 0.000562474774466
Hypercholesterolaemia [dsyn] 0.00056161446118
Measures [qnco] 0.000561053098306
Expected [idcn] 0.000558589183936
Compare [acty] 0.0005571165403
Risks [qlco] 0.000557064554348
Progesterone [horm, phsu, strd] 0.000556070177293
General [spco] 0.000552177575162
American [popg] 0.000551697746742
Severity [qlco] 0.000551527835734
vascular [bpoc] 0.000548633642514
Systolic blood pressure [clna] 0.000548618295476
Physicians [prog] 0.000546793812984
Small [qnco] 0.000545474122041
Formulation [resa] 0.000544608466745
Observational Study [resa] 0.000544059488938
Vascular Malformations [anab] 0.000544033118776
Long [qlco] 0.000543692169594
Female [fndg] 0.00054096374389
Frequent [tmco] 0.000540491712979
Status [qlco] 0.000540349352068
R- [spco] 0.000538896932786
Venous Thromboembolism [patf] 0.000538760082718
Normal [qlco] 0.000538521362386
Appropriate [qlco] 0.000535694099089
Blood Pressure, High [dsyn] 0.000534841084755
objectives [inpr] 0.000534821345761
Lipids [lipd] 0.000532137255199
Community [geoa] 0.000531210725489
Woman [popg] 0.000531089499433
Process [bpoc] 0.000530558359334
Females [fndg] 0.000530078765941
Oestrogens [horm, phsu, strd] 0.000523489871562
Risk factor [qnco] 0.000523417296784
Blood [tisu] 0.000522288374466
formation [biof] 0.000521874355449
Third [qnco] 0.000519052066247
European [popg] 0.000518504808852
Doses [qnco] 0.000518410869888
Young [tmco] 0.000516203872597
Thrombolysis [clna] 0.000514245652221
investigated [ftcn] 0.000512704210871
Discharge [bdsu] 0.000511320723919
Persons [popg] 0.000509880877351
Proportion [qnco] 0.000509495775296
admitted [hlca] 0.000507875457562
medroxyprogesterone acetate [horm, phsu, strd] 0.000506266252663
Ischaemic [ftcn] 0.000505085328923
Stable [qlco] 0.000504696982899
Costs [qnco] 0.000503632446349
ACT [topp] 0.000503370883132
H+ [elii] 0.000502763074555
Lipid-lowering therapy [topp] 0.000500023947478
prospective [resa] 0.00049974436434
Sequential [idcn] 0.000498464615888
Play [dora] 0.000498101349366
Active [ftcn] 0.000497880547278
distribution [idcn] 0.000497032169208
topic6
Estrogen [horm, phsu, strd] 0.00430069878361
Menopause [phsf] 0.00357525970331
Men [popg] 0.00338315744844
Subject [grup] 0.00280235963767
Acute myocardial infarction [dsyn] 0.00261903064272
Breast Cancer [neop] 0.00257286298465
Lipid [lipd] 0.00230506044951
coronary artery disease [dsyn] 0.00221103936278
Estradiol [horm, phsu, strd] 0.00219972385557
Old [tmco] 0.00218392080357
coronary [bpoc] 0.00218324564251
mg% [qnco] 0.0021530176693
N NOS [aapp, imft] 0.00213946504547
Cholesterol [bacs, strd] 0.00212890789752
placebo [topp] 0.00212703343426
Similar [qlco] 0.00204370732726
Decrease [qlco] 0.00201902908785
Combined [qlco] 0.00199026818528
Myocardial Infarction [dsyn] 0.00197036213336
Plasma [bdsu] 0.0019632927711
Survival [acty] 0.00193526866398
Common [qnco] 0.00193260267377
Death [orgf] 0.00186407813552
Benefit [qnco] 0.00185474293722
Drug [phsu] 0.00184726113051
Blood Pressure [orgf] 0.00182264538643
Received [qlco] 0.00182193521437
PREVENT [phsu] 0.00181094376143
Current [tmco] 0.00179810254066
Profile [lbpr] 0.00177943052831
Complications [patf] 0.00177712799382
Oral [spco] 0.00177016511441
Diabetes [dsyn] 0.00174404481552
diabetic [fndg] 0.0017251644847
Drug Therapy [topp] 0.00169267020882
Users [humn] 0.00168013978795
Incidence [qnco] 0.00167515923731
Early [tmco] 0.00161528766648
Reported [inpr] 0.00153715543582
Raloxifene [orch, phsu] 0.00151733045371
Receive [qlco] 0.00149828690744
Guidelines [inpr] 0.00149111517509
symptoms [ftcn] 0.00148345033661
Dose [qnco] 0.00148308565652
Recent [tmco] 0.00148277348847
Decreased [qnco] 0.00148051890464
Likely [qlco] 0.00147224845283
ischaemic heart disease [dsyn] 0.00147217166382
Change [ftcn] 0.00146224895115
Atherosclerosis [dsyn] 0.00143668884791
Total Cholesterol [lbpr] 0.001432494707
Smoking [inbe] 0.00139538648278
Osteoporosis [dsyn] 0.00138957751151
Several [qnco] 0.00136688559463
Known [qlco] 0.00136395666316
mg dl [qnco] 0.00135389939964
Alone [qnco] 0.00135207600554
Diet [food] 0.00134633224591
lowering [spco] 0.0013447038686
High Risk [qlco] 0.00134287578666
considered [idcn] 0.00133615690206
LTD [ortf] 0.00133347320859
intervention [hlca] 0.00132981520376
Concentrations [menp] 0.00132455983307
low [qlco] 0.00130369589635
Agent [chvf] 0.00126705392005
Daily [tmco] 0.00125493851906
Measured [qlco] 0.00125154937894
Confidence Interval [qnco] 0.00124696561395
Prevalence [qnco] 0.00124113391782
Possible [qlco] 0.0012394655474
acute [tmco] 0.00123590872264
Improved [qlco] 0.00122871553949
Available [ftcn] 0.00122829100593
Addition [ftcn] 0.0012246183861
Stroke [dsyn] 0.00121784001307
Progestin [horm, phsu, strd] 0.0012175683906
Well [qlco] 0.00120331986072
History [ocdi] 0.00117993053183
Non [ftcn] 0.00116375171294
days [tmco] 0.00116176977765
Four [qnco] 0.00116144058441
Serum [bdsu] 0.00115478553861
Association [menp] 0.00114853345797
Evaluated [ftcn] 0.00114357062422
Simvastatin [orch, phsu] 0.00113451614944
Benefits [qnco] 0.00113289438747
Obesity [dsyn] 0.0011305619374
Combination [qlco] 0.00111926366167
Diagnosis [fndg] 0.00111291378126
Large [qnco] 0.00110241708611
Overall [inpr] 0.00109607592309
median [spco] 0.0010959070168
Cancer [neop] 0.00108627429899
Continuous [idcn] 0.0010703877266
hypertensive [fndg] 0.00106719270794
Independent [idcn] 0.0010641763153
practice [menp] 0.00104700137396
Percent [qnco] 0.00104653125981
development [phsf] 0.00104351288973
GIVEN [cnce] 0.00104109181859
Low density lipoprotein [aapp, bacs, lipd] 0.00104085937194
Issue [fndg] 0.00102802292027
Relative Risk [qnco] 0.00102573321594
weeks [tmco] 0.00102397677927
Equal [qlco] 0.00102365360997
Take [hlca] 0.00102130387254
Heart disease [dsyn] 0.00101300769387
Cases [ftcn] 0.00101047842855
Examined [fndg] 0.0010042449999
Estrogens [horm, phsu, strd] 0.00100315103553
Primary [qlco] 0.00100192713788
Approach [spco] 0.00100126699602
national [inpr] 0.00100038417471
Odds Ratio [qnco] 0.000999185143691
Cardiac [bpoc] 0.000998057522305
Occur [acty] 0.000994929013707
Lipoprotein [aapp, bacs] 0.000994612400634
Severe [qlco] 0.000993453590719
Elderly [popg] 0.000991889356237
Reducing [qlco] 0.000990085594957
Insulin [aapp, horm, phsu] 0.000989842237872
findings [ftcn] 0.000989367457223
randomized [resa] 0.000983174292414
R- [spco] 0.000982527110591
Range [qnco] 0.000982326355732
Administration [ocac] 0.000981824678345
Atrial Fibrillation [patf] 0.000979312577478
Following [tmco] 0.000978076723094
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000977061985451
Specific [qlco] 0.000976504095178
Events [evnt] 0.000972050412654
Need [qlco] 0.000970030886771
Progestagen [horm, phsu, strd] 0.000967733582741
Action [ftcn] 0.000966705928704
Individual [popg] 0.000962746470059
Test [lbpr] 0.000959713292104
Prognosis [hlca] 0.000958478182442
radiotherapy [inpr] 0.000956644027112
Provide [acty] 0.00095565859654
Initial [tmco] 0.000955102444537
Quality [qlco] 0.000952646816024
Drugs [phsu] 0.000944014185053
Support [medd] 0.000930721033071
Science [ocdi] 0.000930035076933
Currently [tmco] 0.000928478549901
size [spco] 0.000927311713497
Information [idcn] 0.000923515260599
APPEAR [qlco] 0.000923138478676
Late [tmco] 0.000922731445554
Same [qlco] 0.000921805219436
Fasting [fndg] 0.000917517417826
Target [ftcn] 0.000917476581544
Null [qnco] 0.000916813544952
Mechanisms [ftcn] 0.000912943734475
Cholesterol, LDL [bacs, strd] 0.000909167499933
Dependent [qlco] 0.000908858476729
Assess [acty] 0.000905072554255
Hospital [hcro, mnob] 0.000883933719031
setting [ftcn] 0.00087603284227
Care [acty] 0.000873057355352
influential [idcn] 0.000872900642751
Triglycerides [bacs, lipd] 0.000871879420728
Previous [tmco] 0.000871752581506
reviewed [inpr] 0.000867894467427
Young [tmco] 0.000865297847229
Estrogen Replacement Therapy [topp] 0.000861768550375
Aged [orga] 0.000861289939774
HRT [topp] 0.000859978858695
Values [qlco] 0.000856091422158
Purpose [ftcn] 0.000854913437177
Needed [qlco] 0.000854310099776
Ratio [qnco] 0.000847835758147
Main [qlco] 0.000844705447891
IMPACT [gngm] 0.000843798774934
Obtained [ftcn] 0.000840184694193
Duration [tmco] 0.000835062799319
Lp(a) [aapp, bacs] 0.000835039970782
Sex [orgf] 0.000834261932069
Various [irda] 0.000826005052477
function [phsf] 0.000822840727826
I- [inch] 0.000820681979539
Induced [ftcn] 0.000820573588955
condition [dsyn] 0.000820404850374
Affect [menp] 0.000816595495561
Heart failure [dsyn] 0.000814051198791
Secondary Prevention [topp] 0.000812941123293
Marker [clna] 0.000812442396018
investigated [ftcn] 0.000811011849779
progression [patf] 0.000808251764872
Literature [inpr] 0.000807869651923
Evaluation [ftcn] 0.000806951693547
cardiovascular risk factor [dsyn] 0.000803918738139
Cohort [popg] 0.000803288912584
Heart [bpoc] 0.000800182393631
Presence [topp] 0.000799233566476
participants [popg] 0.000798887623196
Risks [qlco] 0.000795731461116
Assessed [acty] 0.000790916347279
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000786789331438
experience [menp] 0.000784637505711
Case [ftcn] 0.000784037812795
Life [idcn] 0.000783246560795
Often [tmco] 0.000781173196502
Future [tmco] 0.000778138457908
Select [acty] 0.000777815680049
Conduct [inbe] 0.000776455920632
Contribute [acty] 0.000775938113971
Children [aggp] 0.000775675379774
Physicians [prog] 0.000773251928827
Clinical Trials [resa] 0.000773195742824
Report [inpr] 0.000769321377397
activity [dora] 0.000768396091938
Event [evnt] 0.000766155014552
System [ftcn] 0.000760187345504
Mechanism [ftcn] 0.000759519733445
Transdermal [ftcn] 0.000757474506219
In [qnco] 0.000756969815796
mmHg [qnco] 0.000755211752713
Parameters [fndg] 0.000752171186292
Phase [tmco] 0.000749414114005
recommendations [idcn] 0.000746471588636
Article [inpr] 0.000746104519533
Cost [qnco] 0.000744725005058
Body Mass Index [diap] 0.000742753414289
Normal [qlco] 0.000742419852796
interventions [hlca] 0.000740884899524
Established [qlco] 0.000740507149015
Regimen [topp] 0.000737680631754
Increasing [ftcn] 0.000736638344478
Relative [famg] 0.000736582078733
Medical [ftcn] 0.000734075513579
Favorable [qlco] 0.000731108562317
Identified [qlco] 0.000730533344921
Process [bpoc] 0.000730108237939
Better [qlco] 0.000728520702992
Response [orga] 0.000727683710348
society [orgt] 0.000724929616348
Therapeutic [topp] 0.000724680646631
Make [ftcn] 0.000723288309209
Safety [hcpp] 0.000722272758712
Hypercholesterolaemia [dsyn] 0.000721813161206
regimens [inpr] 0.000721707112064
Aspirin [orch, phsu] 0.000716602988354
Morbidity [qnco] 0.000715693364448
Out [spco] 0.000713554184585
Second [qnco] 0.000713387605082
Comparison [acty] 0.000712365366914
Relationship [qlco] 0.000710847589702
Now [tmco] 0.000707990061764
Diabetes Mellitus [dsyn] 0.000700260469158
occurrence [ftcn] 0.000694604853317
g% [qnco] 0.000694462387618
mg day [qnco] 0.000691988431291
side effects [ftcn] 0.000689119816376
Persons [popg] 0.000687116754464
objectives [inpr] 0.000686473037998
Thrombolytic Therapy [topp] 0.000683920731299
Estimated [qnco] 0.000682421325961
Published [ocac] 0.000679945002092
Average [qnco] 0.000678981287301
Initiate [idcn] 0.000675114786892
Correlated [qlco] 0.000674422472307
Adjusted [ftcn] 0.000674141783003
Knowledge [inpr] 0.000674075162653
Seen [qlco] 0.000671202576917
Method [inpr] 0.000669700935892
Predictor [idcn] 0.000669092969466
Tamoxifen [orch, phsu] 0.000668642511154
Replacement [topp] 0.000667090867617
Life Style [socb] 0.00066454440593
Control Group [grup] 0.000663345275907
C-reactive protein [aapp, imft] 0.000657156293658
Characteristics [qlco] 0.000657033364347
Venous Thromboembolism [patf] 0.000656880422145
Recently [tmco] 0.000656350860737
vascular [bpoc] 0.000656155231439
Fatal [qlco] 0.00065581845938
mmol/L [qnco] 0.000650558504309
Fibrinogen [aapp, bacs, phsu] 0.000648834719936
Onset [qlco] 0.000648766897617
Community [geoa] 0.000646533223935
Female [fndg] 0.00064452872956
medroxyprogesterone acetate [horm, phsu, strd] 0.000643811465023
Plus [qlco] 0.000642349390401
Model [inpr] 0.000633625673801
Risk factor [qnco] 0.00063261392683
Improvement [cnce] 0.000631107958835
Diseases [dsyn] 0.000630955763202
Costs [qnco] 0.000630672674782
Additional [ftcn] 0.000625901337857
Post-Menopause [orgf] 0.000622887006766
Administered [ftcn] 0.000622152295057
Progestins [horm, phsu, strd] 0.000616784059724
Assigned [ftcn] 0.000615839504747
Limited [ftcn] 0.000614965185634
Controlled [ftcn] 0.000611437763303
Exercise [dora] 0.000609216901058
Cost Effectiveness [qnco] 0.000608889376677
Single [popg] 0.000608577922993
Selective Estrogen Receptor Modulators [horm, phsu] 0.000607563395679
Lipoproteins [aapp, bacs] 0.000601800878286
Cholesterol, HDL [bacs, lipd] 0.000601538342193
Lipids [lipd] 0.000600367112483
Understanding [menp] 0.000599257354125
United States [geoa] 0.000598724280542
Equine [mamm] 0.000598475543085
Proportion [qnco] 0.000593592106455
Concentration [menp] 0.000593086510677
Little NOS [cgab, dsyn] 0.000592057399012
Long [qlco] 0.000589776150575
Congestive heart failure [dsyn] 0.000589002412474
Diastolic blood pressure [clna] 0.000588886861974
Adults [aggp] 0.000587865387695
adverse effects [ftcn] 0.000586647813433
Breast [bpoc] 0.000585836052061
Sample [sbst] 0.00058572736461
Systolic blood pressure [clna] 0.000584633328146
Education [edac] 0.000583264794523
Small [qnco] 0.000582547700633
Observational Study [resa] 0.000579674343848
mediated [socb] 0.000577903956956
Lipoprotein (a) [aapp, bacs] 0.000576156128269
Few [qnco] 0.000575913043859
???lead [elii, hops] 0.000574825650255
Frequently [tmco] 0.000573853258963
Estrogen Replacement [topp] 0.000572822915996
Status [qlco] 0.000572660965227
cardiovascular events [fndg] 0.000570771243372
Stage [tmco] 0.000569935704873
Compliance [qnco] 0.0005682408438
Question [inpr] 0.00056769861569
Bone Mineral Density [clna] 0.000564963707751
frequency [qnco] 0.000564485600149
prospective [resa] 0.000562989499614
Compound [qlco] 0.000558940818904
Occurred [acty] 0.000558790612366
Measure [qnco] 0.00055854723402
Effectiveness [qlco] 0.000558175968316
Dietary [food] 0.000557978668311
Recommended [idcn] 0.000557007693261
Syndromes, Acute Coronary [dsyn] 0.000553031652724
density [qnco] 0.000552638401274
Insulin Sensitivity [patf] 0.000550573871668
Concern [idcn] 0.000550056820112
Physical activity [dora] 0.000548391599338
Human [humn] 0.000545370333778
Detection [topp] 0.000543657780828
Five [qnco] 0.000540863089805
Part [spco] 0.000540343324455
Prognostic Factor [clna] 0.000539656145236
Ireland [geoa] 0.000539564366429
strategies [menp] 0.000539319505494
Beta-Blockers [phsu] 0.00053792549905
Past [tmco] 0.000537745946966
investigate [ftcn] 0.000536812858354
Class [inpr] 0.000533002787725
Calcium [bacs, elii, phsu] 0.000531452731489
Assessment [hlca] 0.000530100080137
Glucose [bacs, carb, phsu] 0.000529184584392
Medication [phsu] 0.000523433006506
American [popg] 0.000523181141771
Treatments [topp] 0.000522303186388
Consecutive [qlco] 0.000520873620273
tibolone [phsu, strd] 0.000520009981231
Application [hlca] 0.000520009697886
Type [qlco] 0.00051999935281
Elevated [qlco] 0.000519616333653
Cardiology [bmod] 0.000518783433966
Value [qnco] 0.000517931620127
smokers [fndg] 0.000517065881225
hormone replacement [topp] 0.000516223854944
Strong [qlco] 0.000516070385393
Central [spco] 0.000515849316059
Documented [hlca] 0.000515662479537
Arterial [bpoc] 0.000515568481218
Chemoprevention [topp] 0.000514455676865
H+ [elii] 0.000514094569055
Progesterone [horm, phsu, strd] 0.000511943340849
Ii [aapp] 0.000509371054408
European [popg] 0.000509278038834
Hormone [horm] 0.000509072935091
Never [tmco] 0.00050694082623
Analyzed [resa] 0.000505744893769
month [tmco] 0.000504851796718
Start [tmco] 0.000503483008253
Woman [popg] 0.000503272646385
Ischaemia [dsyn] 0.000503204933873
reductions [npop] 0.0005024599533
prescribed [hlca] 0.000502172992191
Indicated [fndg] 0.000502091720815
menopausal symptoms [sosy] 0.000499813518811
Address [inpr] 0.000498255617052
Successful [qlco] 0.000496547339051
Conjugated estrogen [horm, phsu, strd] 0.000495889952117
Expected [idcn] 0.000493498065377
Ischaemic [ftcn] 0.000493304046207
Statins [orch, phsu] 0.000493279854451
trends [tmco] 0.000493262896496
Survivors [podg] 0.000491888893213
topic7
Estrogen [horm, phsu, strd] 0.00431723385046
Menopause [phsf] 0.00416359763908
Acute myocardial infarction [dsyn] 0.00337191578172
Breast Cancer [neop] 0.00302713780101
Plasma [bdsu] 0.00295325653571
Blood Pressure [orgf] 0.00263116188881
Benefit [qnco] 0.00250223974391
Oral [spco] 0.00249052061121
Lipid [lipd] 0.00237470307399
N NOS [aapp, imft] 0.00236096745516
Myocardial Infarction [dsyn] 0.002281606762
placebo [topp] 0.00222582600271
Death [orgf] 0.00215565435124
coronary artery disease [dsyn] 0.00212779275457
Reported [inpr] 0.00210459877975
randomized [resa] 0.00208261066737
mg% [qnco] 0.00202822220251
Common [qnco] 0.00195978400023
Receive [qlco] 0.00193315214586
Measured [qlco] 0.00187906366705
Old [tmco] 0.00186470356635
PREVENT [phsu] 0.00186450242082
Survival [acty] 0.0018632867146
Men [popg] 0.00185571918101
Users [humn] 0.00183510082433
Drug [phsu] 0.00180518308908
Stroke [dsyn] 0.00177458262258
Change [ftcn] 0.00175596674103
Drug Therapy [topp] 0.00174786751222
Cases [ftcn] 0.0017268574241
Current [tmco] 0.001668426384
Cholesterol [bacs, strd] 0.00163826574961
Incidence [qnco] 0.0016156049518
Decrease [qlco] 0.00157898878072
Subject [grup] 0.00157494887638
Overall [inpr] 0.00153128874396
Alone [qnco] 0.00151333914822
coronary [bpoc] 0.00147881825577
Estradiol [horm, phsu, strd] 0.0014781417034
Aged [orga] 0.00146658436981
High Risk [qlco] 0.00145698565861
Hospital [hcro, mnob] 0.00145492398384
Heart disease [dsyn] 0.0014532397626
Received [qlco] 0.00144010447533
Diabetes [dsyn] 0.00143922463744
Complications [patf] 0.00143080526808
Combined [qlco] 0.0014203094463
Association [menp] 0.00141448154087
radiotherapy [inpr] 0.00141216958451
Likely [qlco] 0.00139525249241
symptoms [ftcn] 0.00136025941832
diabetic [fndg] 0.00136015984687
Profile [lbpr] 0.00135924865156
ischaemic heart disease [dsyn] 0.00133437716699
Diet [food] 0.00133410665331
Dose [qnco] 0.00132001386703
strategies [menp] 0.00131922612225
Progestin [horm, phsu, strd] 0.00131452902389
Prevalence [qnco] 0.00131373695129
Triglycerides [bacs, lipd] 0.00131363544173
Following [tmco] 0.00131162234439
Benefits [qnco] 0.00130056205704
Known [qlco] 0.00129873394899
APPEAR [qlco] 0.0012969602137
Agent [chvf] 0.00128787844252
Recent [tmco] 0.00128657328659
Similar [qlco] 0.00128369587529
Smoking [inbe] 0.00128303910906
Improved [qlco] 0.00127979201116
Null [qnco] 0.00126892149282
Take [hlca] 0.00126804984117
Combination [qlco] 0.00125988676967
Decreased [qnco] 0.00125473796938
Confidence Interval [qnco] 0.001238144248
Early [tmco] 0.00119425213381
considered [idcn] 0.00118941773809
Large [qnco] 0.00118282166722
Raloxifene [orch, phsu] 0.00116504681584
Simvastatin [orch, phsu] 0.00116471189089
Atherosclerosis [dsyn] 0.00116293989352
Cardiac [bpoc] 0.00115354577915
Non [ftcn] 0.00115051284886
weeks [tmco] 0.00115012404147
IMPACT [gngm] 0.00114497845104
findings [ftcn] 0.00114035933546
Estrogen Replacement Therapy [topp] 0.00113547924857
Target [ftcn] 0.00113098421596
Well [qlco] 0.00112949086208
development [phsf] 0.00112044330989
Occur [acty] 0.00111827664166
Osteoporosis [dsyn] 0.00111499699333
Transdermal [ftcn] 0.00110989678119
setting [ftcn] 0.00110880960955
Possible [qlco] 0.00110691343305
Estrogens [horm, phsu, strd] 0.00110606175971
Examined [fndg] 0.001102037326
Diagnosis [fndg] 0.00110082700402
Available [ftcn] 0.00109940927772
intervention [hlca] 0.00109670642754
low [qlco] 0.00109214785805
acute [tmco] 0.00108923528168
Odds Ratio [qnco] 0.00107736827167
Range [qnco] 0.00107578118542
mg dl [qnco] 0.00107456089377
Therapeutic [topp] 0.00107313144652
History [ocdi] 0.00107293023918
Percent [qnco] 0.0010640091957
Progestagen [horm, phsu, strd] 0.00106394181966
Make [ftcn] 0.00106296668797
Morbidity [qnco] 0.00106067286276
Independent [idcn] 0.00105873815946
days [tmco] 0.00105174061991
Equal [qlco] 0.00104937276737
Individual [popg] 0.00104444195775
Secondary Prevention [topp] 0.00104020614078
Medical [ftcn] 0.00103348639963
Parameters [fndg] 0.00103152366563
Provide [acty] 0.0010309676656
Science [ocdi] 0.00102923200144
Cost Effectiveness [qnco] 0.00102705918478
Four [qnco] 0.00101974299442
cardiovascular risk factor [dsyn] 0.00101175894473
Several [qnco] 0.00100219644022
Assess [acty] 0.000999029746185
Insulin [aapp, horm, phsu] 0.000996962753845
Predictor [idcn] 0.000992328953077
Continuous [idcn] 0.000980363515403
Heart [bpoc] 0.000979541046811
Need [qlco] 0.000977525936491
condition [dsyn] 0.000976430580287
Cost [qnco] 0.000973052974183
Concentrations [menp] 0.000966389182205
Evaluated [ftcn] 0.000963488010529
Drugs [phsu] 0.000960975219816
experience [menp] 0.000959781789741
Information [idcn] 0.000959404682281
Exercise [dora] 0.00095901213716
Often [tmco] 0.000954395956406
Main [qlco] 0.000948319972895
Aspirin [orch, phsu] 0.00094669138178
Improvement [cnce] 0.000946619724218
Diseases [dsyn] 0.000944021232226
Serum [bdsu] 0.000941864437102
Onset [qlco] 0.00094179964705
hypertensive [fndg] 0.000940473919275
Guidelines [inpr] 0.000932990786162
Needed [qlco] 0.000931179140145
Relationship [qlco] 0.000929762343462
Addition [ftcn] 0.000928890558358
practice [menp] 0.000920422127524
lowering [spco] 0.000912931633855
Total Cholesterol [lbpr] 0.000910014933847
Values [qlco] 0.000907230407669
Atrial Fibrillation [patf] 0.00090484341873
HRT [topp] 0.000904547324947
Past [tmco] 0.00090428216842
Comparison [acty] 0.000903598085039
Heart failure [dsyn] 0.000902861141471
Obesity [dsyn] 0.000898751927049
recommendations [idcn] 0.000893817328263
Fasting [fndg] 0.00089140139622
Lp(a) [aapp, bacs] 0.00089092092578
Events [evnt] 0.000890765048774
function [phsf] 0.000874578665513
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000873958571111
In [qnco] 0.000873949017063
Life [idcn] 0.000872755280989
Administration [ocac] 0.000872622400327
Selective Estrogen Receptor Modulators [horm, phsu] 0.000870282031039
Marker [clna] 0.000868450383602
Elderly [popg] 0.000862390626998
Select [acty] 0.000855060591276
Phase [tmco] 0.000853906847295
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000853225590755
influential [idcn] 0.000850776473688
I- [inch] 0.000846686833454
Assessed [acty] 0.00083740266342
Conduct [inbe] 0.000833628097532
GIVEN [cnce] 0.000831066208237
Previous [tmco] 0.000827791103531
Primary [qlco] 0.000826294625536
median [spco] 0.000823483379042
Literature [inpr] 0.000822441759382
Part [spco] 0.000821251174474
Evaluation [ftcn] 0.000820942550719
Report [inpr] 0.000815887737975
R- [spco] 0.00081042261894
Ireland [geoa] 0.000810156148565
Clinical Trials [resa] 0.000806255818139
Daily [tmco] 0.000801904480154
Currently [tmco] 0.000800257856723
Tamoxifen [orch, phsu] 0.000799183678716
Increasing [ftcn] 0.000796780253685
Duration [tmco] 0.000795477888088
Prognosis [hlca] 0.000795343239858
Average [qnco] 0.000793782548433
C-reactive protein [aapp, imft] 0.00079376706481
Hypercholesterolaemia [dsyn] 0.000790649063553
Cholesterol, LDL [bacs, strd] 0.000789956627114
Quality [qlco] 0.000787675592582
size [spco] 0.000782018091867
Approach [spco] 0.000780389649354
Lipoprotein [aapp, bacs] 0.000776707515287
Progesterone [horm, phsu, strd] 0.00077651153249
Induced [ftcn] 0.000772074206458
mmol/L [qnco] 0.000771565880487
activity [dora] 0.000764066226735
Response [orga] 0.00075975757697
Presence [topp] 0.000759130038134
Second [qnco] 0.00075874616738
participants [popg] 0.000753002329456
Knowledge [inpr] 0.000750505480882
Sex [orgf] 0.000747488700004
Lipids [lipd] 0.000739758970966
investigated [ftcn] 0.000739737117307
mmHg [qnco] 0.000738053121712
LTD [ortf] 0.000735666091269
Article [inpr] 0.000733422099619
Community [geoa] 0.000732079499467
Adjusted [ftcn] 0.000729096461418
Characteristics [qlco] 0.00072527930636
Established [qlco] 0.000723719447878
vascular [bpoc] 0.000722574169417
Issue [fndg] 0.00071930680226
Few [qnco] 0.000715129353916
Frequently [tmco] 0.00071488968777
Low density lipoprotein [aapp, bacs, lipd] 0.000714108295824
Case [ftcn] 0.000712647919916
Progestins [horm, phsu, strd] 0.000710513948064
Long [qlco] 0.000709394972505
Diastolic blood pressure [clna] 0.000707430706082
H+ [elii] 0.000707354554847
Favorable [qlco] 0.000705660560431
society [orgt] 0.000704738105455
Prognostic Factor [clna] 0.000704615710503
tibolone [phsu, strd] 0.000702116735373
Test [lbpr] 0.000698160789023
Care [acty] 0.000695773607421
Observational Study [resa] 0.000695385438578
Young [tmco] 0.000694700014923
Venous Thromboembolism [patf] 0.000692232893536
Purpose [ftcn] 0.000687003886856
reviewed [inpr] 0.000685472948772
Support [medd] 0.000685460454486
admitted [hlca] 0.000683584108822
Cancer [neop] 0.000683167488242
Identified [qlco] 0.000683144009722
Recently [tmco] 0.000679726299758
smokers [fndg] 0.000678549316828
Mechanisms [ftcn] 0.000675748005354
Same [qlco] 0.000674147308255
Reducing [qlco] 0.000672097244639
Relative Risk [qnco] 0.000671294131221
Effectiveness [qlco] 0.000668571219578
American [popg] 0.00066811473267
progression [patf] 0.000667952704009
Recommended [idcn] 0.000667923754333
Physical activity [dora] 0.0006658490106
Estrogen Replacement [topp] 0.000662245432134
month [tmco] 0.000662196957297
Physicians [prog] 0.000660920410279
Body Mass Index [diap] 0.000660732496288
Initial [tmco] 0.00065818464461
Small [qnco] 0.00065482084572
Type [qlco] 0.000654516056207
Estimated [qnco] 0.000653213349735
objectives [inpr] 0.000652226795076
Fibrinogen [aapp, bacs, phsu] 0.000649010783023
Seen [qlco] 0.000646896560541
Event [evnt] 0.000646096932317
prospective [resa] 0.000646012606462
Risk factor [qnco] 0.000645989209863
Cardiology [bmod] 0.000641582270242
Surgery [bmod] 0.00064071563102
Risks [qlco] 0.000639810863614
Published [ocac] 0.000637998877215
Specific [qlco] 0.00063460888515
System [ftcn] 0.000634463146108
Assigned [ftcn] 0.000634193951533
Alternative [cnce] 0.000634155347436
interventions [hlca] 0.000630670425258
Play [dora] 0.000629533991246
Normal [qlco] 0.000629137705796
Female [fndg] 0.00062870816539
Costs [qnco] 0.000628571874356
Glucose [bacs, carb, phsu] 0.000628401748312
regimens [inpr] 0.00062823375201
Life Style [socb] 0.00062625434474
Endothelial [tisu] 0.000622408656957
Human [humn] 0.00062205916181
mg day [qnco] 0.000621483121237
Syndromes, Acute Coronary [dsyn] 0.000615790361363
Class [inpr] 0.000610025231903
Relative [famg] 0.000609007955931
Limited [ftcn] 0.000608462884805
Occurred [acty] 0.000607418471929
Model [inpr] 0.000603968691985
Delay [tmco] 0.0005999582692
Sequential [idcn] 0.000598305078268
Controlled [ftcn] 0.000595880254129
Menopausal [phsf] 0.000594400000266
distribution [idcn] 0.000593669583273
Safety [hcpp] 0.000593321247725
Infarction [patf] 0.000591226773508
Replacement [topp] 0.000590158193961
Additional [ftcn] 0.000589447134701
Administered [ftcn] 0.000588760072717
Education [edac] 0.000587725529345
Five [qnco] 0.00058632022494
Stage [tmco] 0.000584828908443
Out [spco] 0.000583941523777
Indicated [fndg] 0.000583422852781
United States [geoa] 0.000582389457084
Thrombolytic Therapy [topp] 0.000581860317092
Process [bpoc] 0.000580621055771
Compare [acty] 0.000579742518783
prognostic [inpr] 0.000578466695457
cardiovascular events [fndg] 0.000576867426961
Regimen [topp] 0.000575750465057
Dependent [qlco] 0.000573667202473
Future [tmco] 0.000570924497297
Index [inpr] 0.0005707924039
Central [spco] 0.000570069402744
Treatments [topp] 0.000569482062402
Point [qnco] 0.000569379515882
Diabetes Mellitus [dsyn] 0.000568700446217
Severity [qlco] 0.000566046587506
Single [popg] 0.000565845035464
Presentation [idcn] 0.000564437620226
Now [tmco] 0.000562015320131
investigate [ftcn] 0.000560786118297
Severe [qlco] 0.000560674721681
Affect [menp] 0.000560154165133
variables [qlco] 0.000560136710276
Ratio [qnco] 0.000558102996435
Measure [qnco] 0.000557275642585
Contribute [acty] 0.000557134677924
Compound [qlco] 0.000556398272678
Insulin Sensitivity [patf] 0.000555186864386
Chemoprevention [topp] 0.000555135704087
Plus [qlco] 0.000553933846601
Concentration [menp] 0.000553871562155
adverse effects [ftcn] 0.000552526363319
Congestive heart failure [dsyn] 0.000552522191724
g% [qnco] 0.000552313259975
Initiate [idcn] 0.00055061499238
Equine [mamm] 0.000549712156754
Cohort [popg] 0.00054849514742
Bleeding [patf] 0.000548283478645
Status [qlco] 0.000547973606204
Never [tmco] 0.000547235576899
Diagnosed [fndg] 0.000546949938064
Adjustment [inbe] 0.000545597525651
Ischaemic [ftcn] 0.000543686866726
Various [irda] 0.00054141219593
European [popg] 0.000541378677364
Proportion [qnco] 0.000540521317592
Conjugated estrogen [horm, phsu, strd] 0.000540514322983
Little NOS [cgab, dsyn] 0.000540144547205
Statins [orch, phsu] 0.000538860777897
Stable [qlco] 0.000538465233431
Expected [idcn] 0.000537974450881
Woman [popg] 0.000537858036796
Dietary [food] 0.000536092494263
Systolic blood pressure [clna] 0.000535783885998
Extent [spco] 0.000535529051281
Presented [idcn] 0.000535063601955
Mechanism [ftcn] 0.000533897417749
Patterns [spco] 0.000532194981116
Hormone [horm] 0.000531540296533
Complex [qlco] 0.000530648321064
Thrombolysis [clna] 0.000527029445375
Children [aggp] 0.000526955478397
Therapies [topp] 0.000525605800951
Method [inpr] 0.000523797033012
mediated [socb] 0.000523635204293
Concern [idcn] 0.000522692518485
QT [qnco] 0.000508469547917
Lipoproteins [aapp, bacs] 0.000507993128029
Persons [popg] 0.000507712943951
Approaches [spco] 0.000507606209594
Infants [aggp] 0.000505987044023
Survivors [podg] 0.000502968905043
Adults [aggp] 0.00050273669855
Failure [ftcn] 0.000501140680766
Died [orgf] 0.000500367748876
Discharge [bdsu] 0.000499887561511
prescribed [hlca] 0.000496949260091
Direct [qlco] 0.000496281463136
Documented [hlca] 0.000494925974806
Required [ftcn] 0.000494817063334
side effects [ftcn] 0.000494017777122
occurrence [ftcn] 0.000492432563067
Application [hlca] 0.00049125852898
Compliance [qnco] 0.000488240761385
Help [socb] 0.000487964254935
reductions [npop] 0.000487210280168
Control Group [grup] 0.000486950033982
Blood [tisu] 0.00048251325414
Beta-Blockers [phsu] 0.000482391159498
topic8
Estrogen [horm, phsu, strd] 0.00669766015129
Men [popg] 0.00436851693977
Acute myocardial infarction [dsyn] 0.00278338823909
coronary [bpoc] 0.00266869048498
Receive [qlco] 0.002642022115
Menopause [phsf] 0.00249153975274
Breast Cancer [neop] 0.00249032888556
Blood Pressure [orgf] 0.00235903232282
N NOS [aapp, imft] 0.00231083675219
mg% [qnco] 0.00220866028593
Stroke [dsyn] 0.00214472244888
Old [tmco] 0.00214405872888
Plasma [bdsu] 0.00214285530705
Profile [lbpr] 0.00209784516495
Non [ftcn] 0.00209301748279
Combined [qlco] 0.00208233709114
Oral [spco] 0.00205684914782
placebo [topp] 0.00203764773726
Lipid [lipd] 0.00202684783301
Subject [grup] 0.00195970216157
Cholesterol [bacs, strd] 0.00194815697178
Myocardial Infarction [dsyn] 0.00193528313377
randomized [resa] 0.00191427930368
Similar [qlco] 0.00187061423754
Death [orgf] 0.00177122937756
Drug Therapy [topp] 0.00177068664762
Survival [acty] 0.00176403849819
Simvastatin [orch, phsu] 0.0017385524007
Incidence [qnco] 0.00173397072546
Benefit [qnco] 0.00172695170739
Received [qlco] 0.00172097445097
Diabetes [dsyn] 0.0017201434255
Current [tmco] 0.00169616009895
Cases [ftcn] 0.00166277571855
Decrease [qlco] 0.00166106586323
Individual [popg] 0.00163328420835
Confidence Interval [qnco] 0.00162972622434
Measured [qlco] 0.00162849056042
Reported [inpr] 0.00162013381533
Heart disease [dsyn] 0.00161549444312
Association [menp] 0.00161156131854
low [qlco] 0.00157989478556
symptoms [ftcn] 0.00157818684424
Cancer [neop] 0.00155205242043
Equal [qlco] 0.00153869388693
Combination [qlco] 0.0015379921024
coronary artery disease [dsyn] 0.00153316845946
Progestin [horm, phsu, strd] 0.00152979764724
PREVENT [phsu] 0.00152259246144
Need [qlco] 0.00150512643369
diabetic [fndg] 0.00147297874157
High Risk [qlco] 0.00146240625789
Change [ftcn] 0.00146102277183
Common [qnco] 0.00145578278156
Raloxifene [orch, phsu] 0.00142946400569
development [phsf] 0.0014228842744
Atherosclerosis [dsyn] 0.00142250504321
Decreased [qnco] 0.00141816348542
Early [tmco] 0.00140816560081
Users [humn] 0.00140527612198
Recent [tmco] 0.00139514299424
Estradiol [horm, phsu, strd] 0.0013670670699
days [tmco] 0.00135867152159
APPEAR [qlco] 0.00134959091863
considered [idcn] 0.00134341411108
findings [ftcn] 0.0013318940089
Diet [food] 0.00133116586585
Drugs [phsu] 0.0013294180124
C-reactive protein [aapp, imft] 0.00130940841766
Addition [ftcn] 0.00129713245909
intervention [hlca] 0.00128444050018
Drug [phsu] 0.00128432426059
Alone [qnco] 0.00128124703838
Null [qnco] 0.00128103760549
Possible [qlco] 0.00128029675236
Science [ocdi] 0.0012787772152
Improved [qlco] 0.00127779196358
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00125498526594
Range [qnco] 0.00124999616035
Cardiac [bpoc] 0.00124685888283
Osteoporosis [dsyn] 0.00122781112123
Quality [qlco] 0.00121644031195
Prevalence [qnco] 0.00119827739009
ischaemic heart disease [dsyn] 0.00116127702537
Complications [patf] 0.00116114156884
Percent [qnco] 0.00115774429974
hypertensive [fndg] 0.00114497315738
Relationship [qlco] 0.00114107327636
mg dl [qnco] 0.00113970670455
Elderly [popg] 0.00113577906536
Concentrations [menp] 0.00112900650169
Agent [chvf] 0.00112864489699
Odds Ratio [qnco] 0.00111794906343
Smoking [inbe] 0.00111765001293
Morbidity [qnco] 0.00111609175815
Take [hlca] 0.0011122425579
Dose [qnco] 0.00110899737322
Daily [tmco] 0.00110334336641
lowering [spco] 0.00108839377714
Lp(a) [aapp, bacs] 0.00108571604317
Likely [qlco] 0.00108403994282
Purpose [ftcn] 0.00108247096871
Target [ftcn] 0.00108140115156
Assess [acty] 0.00107442823293
History [ocdi] 0.00107189729274
Large [qnco] 0.00107001841794
Events [evnt] 0.0010698911494
national [inpr] 0.00106824906316
Independent [idcn] 0.00106433127852
Low density lipoprotein [aapp, bacs, lipd] 0.00106285746468
Well [qlco] 0.00105176676259
Overall [inpr] 0.00105054584295
HRT [topp] 0.00104076333414
Information [idcn] 0.00103361417733
Aged [orga] 0.00102346617655
mmHg [qnco] 0.00102301637201
Estrogens [horm, phsu, strd] 0.00101963224779
acute [tmco] 0.00101566428327
Specific [qlco] 0.00101175149081
experience [menp] 0.0010046362029
Improvement [cnce] 0.000997313524312
Compare [acty] 0.000995583648764
Primary [qlco] 0.000990606839391
Main [qlco] 0.000988093596247
GIVEN [cnce] 0.00098031262046
practice [menp] 0.000973292524952
Test [lbpr] 0.000973266814886
Previous [tmco] 0.000966534557316
Established [qlco] 0.000966254735141
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000965931926072
Increasing [ftcn] 0.000965230446274
Therapeutic [topp] 0.000961418599526
Clinical Trials [resa] 0.000959764714071
Care [acty] 0.000958658114306
LTD [ortf] 0.000955385343287
Parameters [fndg] 0.000951465218746
Induced [ftcn] 0.000944273865508
Total Cholesterol [lbpr] 0.000944241123087
Post-Menopause [orgf] 0.000942226283005
participants [popg] 0.000941428167083
Atrial Fibrillation [patf] 0.00094124270974
Diagnosis [fndg] 0.000940916014391
Onset [qlco] 0.000939511963892
Available [ftcn] 0.000938220300022
Heart failure [dsyn] 0.000934885735372
Identified [qlco] 0.00093308915167
Progestagen [horm, phsu, strd] 0.000932974036598
Life [idcn] 0.000922953379708
Benefits [qnco] 0.000922894842044
Recently [tmco] 0.000922137999865
Prognosis [hlca] 0.000921848153085
Hospital [hcro, mnob] 0.000918910047883
Secondary Prevention [topp] 0.000918405660357
Guidelines [inpr] 0.000908816266257
Occur [acty] 0.000904863532469
Estrogen Replacement Therapy [topp] 0.0009036060939
Continuous [idcn] 0.000902759345996
Aspirin [orch, phsu] 0.000899146084506
R- [spco] 0.000898974549995
Triglycerides [bacs, lipd] 0.000897822198123
Select [acty] 0.000884878707056
Approach [spco] 0.000881830101698
Relative [famg] 0.000881033628352
Physicians [prog] 0.000877732438816
vascular [bpoc] 0.000874383455494
Administration [ocac] 0.000873912283669
Sex [orgf] 0.000872192011217
Several [qnco] 0.000867886209426
Currently [tmco] 0.000866151666038
I- [inch] 0.000866115128962
Heart [bpoc] 0.000862340749922
Past [tmco] 0.000858488804261
Knowledge [inpr] 0.00085675241107
Values [qlco] 0.000856224022979
Following [tmco] 0.000848588203352
Obesity [dsyn] 0.000848440384171
function [phsf] 0.000848276711623
Relative Risk [qnco] 0.000846520066365
Phase [tmco] 0.000832049233406
Body Mass Index [diap] 0.000831678173788
activity [dora] 0.000828016515283
mmol/L [qnco] 0.000827453069438
strategies [menp] 0.000827363677716
Diastolic blood pressure [clna] 0.000827228839592
radiotherapy [inpr] 0.000825940189263
Various [irda] 0.000821745870616
weeks [tmco] 0.000819405918321
Process [bpoc] 0.00081937626478
Response [orga] 0.000816283724259
median [spco] 0.000813153506839
Favorable [qlco] 0.000807509693909
Needed [qlco] 0.000805747880992
Fasting [fndg] 0.000805361045914
Average [qnco] 0.000798120901285
Comparison [acty] 0.000796847899364
Cost [qnco] 0.000795738315339
Provide [acty] 0.000793468083725
Adjusted [ftcn] 0.000790892850677
Often [tmco] 0.000790598174764
Make [ftcn] 0.00078745515491
Dependent [qlco] 0.000786729484927
Assessed [acty] 0.000781451384071
objectives [inpr] 0.000780136152373
Literature [inpr] 0.000779096297663
influential [idcn] 0.000772617024452
Hormone [horm] 0.000772298748115
Selective Estrogen Receptor Modulators [horm, phsu] 0.000770760035388
Report [inpr] 0.000767459140009
Menopausal [phsf] 0.000766446606386
Replacement [topp] 0.000766176351308
Action [ftcn] 0.000765878040522
Ischaemic [ftcn] 0.000762190850551
Conduct [inbe] 0.000756418919748
IMPACT [gngm] 0.000755150842753
Examined [fndg] 0.000749640564169
Same [qlco] 0.000748961337223
month [tmco] 0.000748822938605
Medical [ftcn] 0.000746560361921
Affect [menp] 0.000744427391556
Marker [clna] 0.000744076071044
Predictor [idcn] 0.000742691930131
Published [ocac] 0.000738730530012
Four [qnco] 0.000736298910892
Progestins [horm, phsu, strd] 0.000734956168694
Issue [fndg] 0.000734428516534
Evaluated [ftcn] 0.000734191598074
Type [qlco] 0.000732030772314
Event [evnt] 0.000730810818604
setting [ftcn] 0.000729907154506
Known [qlco] 0.000728121303099
Lipoprotein [aapp, bacs] 0.000725772413734
adverse effects [ftcn] 0.000721371703803
society [orgt] 0.000719310910273
Transdermal [ftcn] 0.000716954589197
Diseases [dsyn] 0.000714419764036
Obtained [ftcn] 0.000712654714771
Children [aggp] 0.000710955839878
Duration [tmco] 0.000707423923589
Serum [bdsu] 0.000707386769124
variables [qlco] 0.000706806871772
condition [dsyn] 0.00070603398831
Model [inpr] 0.000705587762145
Evaluation [ftcn] 0.000704331067356
Concern [idcn] 0.000703907514959
mg day [qnco] 0.000703636313773
Reducing [qlco] 0.00070072456933
Cholesterol, LDL [bacs, strd] 0.000697413662318
Long [qlco] 0.000697217775238
H+ [elii] 0.000693571095947
Mechanism [ftcn] 0.000692243140408
Second [qnco] 0.000689005721391
Hypercholesterolaemia [dsyn] 0.000687730028888
Compound [qlco] 0.000682735691876
Systolic blood pressure [clna] 0.000680719359594
Breast [bpoc] 0.000679187043552
Interaction [ftcn] 0.000676257207993
Better [qlco] 0.000676054123473
Insulin [aapp, horm, phsu] 0.00067528478442
Characteristics [qlco] 0.000674944887133
tibolone [phsu, strd] 0.000673231385515
Part [spco] 0.000671617133057
Severe [qlco] 0.000671560129976
Lipoprotein (a) [aapp, bacs] 0.000671555940998
Died [orgf] 0.000671001860182
Ratio [qnco] 0.000670797173071
Out [spco] 0.000664368030053
Thrombolytic Therapy [topp] 0.000664138746356
reviewed [inpr] 0.000661328693228
Treatments [topp] 0.000660233884951
progression [patf] 0.000657916550668
Normal [qlco] 0.000656228065621
cardiovascular risk factor [dsyn] 0.000655014805007
Limited [ftcn] 0.000652317882626
Adjustment [inbe] 0.000649612312702
Case [ftcn] 0.000648666876254
Contrast [qlco] 0.000647624182072
Exercise [dora] 0.000646897116087
Lipoproteins [aapp, bacs] 0.000645575792811
recommendations [idcn] 0.00064549302715
Concentration [menp] 0.000644081166706
Article [inpr] 0.000643863442623
Infarction [patf] 0.000642312300782
Safety [hcpp] 0.000639786985378
Compliance [qnco] 0.000636268021971
Lipids [lipd] 0.000635182086751
Progesterone [horm, phsu, strd] 0.000634276353469
System [ftcn] 0.000634222333556
Risks [qlco] 0.000632852284749
Presence [topp] 0.000632346196601
In [qnco] 0.000630841411684
Fatal [qlco] 0.000629037432916
side effects [ftcn] 0.000622149607603
Support [medd] 0.000619553454686
Bleeding [patf] 0.000619322391667
Administered [ftcn] 0.000618463803877
Prognostic Factor [clna] 0.000617215243906
Cohort [popg] 0.00061299163211
Insulin Sensitivity [patf] 0.000607992881428
prognostic [inpr] 0.000607941526287
Control Group [grup] 0.000607631475642
Fibrinogen [aapp, bacs, phsu] 0.000607082851621
Analyzed [resa] 0.000605663674101
Woman [popg] 0.000605070989912
Physical activity [dora] 0.000602064981495
lack [qlco] 0.000600314580319
hormone replacement [topp] 0.0005990343073
interventions [hlca] 0.000596640879958
properties [qlco] 0.000595626156791
mediated [socb] 0.000593490781651
smokers [fndg] 0.000591597805945
g% [qnco] 0.000591039702649
Costs [qnco] 0.000591004542443
Effectiveness [qlco] 0.000590570945085
Initial [tmco] 0.000588551076577
Venous Thromboembolism [patf] 0.000585705076365
DOUBLE BLIND [resa] 0.000584299116395
atorvastatin [orch, phsu] 0.000583424580213
Moderate [qlco] 0.000582745569986
Occurred [acty] 0.00058101364902
Congestive heart failure [dsyn] 0.000580804146348
Strong [qlco] 0.000578945413478
Thrombolysis [clna] 0.00057796404665
Defined [cnce] 0.000577747252465
medroxyprogesterone acetate [horm, phsu, strd] 0.000576384913394
size [spco] 0.000572863188575
fluvastatin [orch, phsu] 0.00057017902916
Controlled [ftcn] 0.000568400288832
Young [tmco] 0.000567419267503
Plus [qlco] 0.000566332669459
Beta-Blockers [phsu] 0.000565073549195
Formulation [resa] 0.000564996465998
Cholesterol, HDL [bacs, lipd] 0.000564840991825
Cardiology [bmod] 0.00056440704044
Thrombosis [patf] 0.000564195397655
Life Style [socb] 0.000562865071821
Lipid-lowering therapy [topp] 0.000560500341565
Ireland [geoa] 0.000557445897682
Estimated [qnco] 0.000554592909923
Persons [popg] 0.000552539970341
Discharge [bdsu] 0.000548902017658
Alternative [cnce] 0.000548262869405
Females [fndg] 0.000547896107132
???lead [elii, hops] 0.000545929295664
Risk factor [qnco] 0.000541391692286
investigated [ftcn] 0.000541259537393
Additional [ftcn] 0.000538239520096
Stage [tmco] 0.000535554491784
Central [spco] 0.000535271160092
Education [edac] 0.000534258516044
Expression [topp] 0.00053152739476
Consecutive [qlco] 0.00053072995859
Recommended [idcn] 0.000530491786369
Equine [mamm] 0.000527532752974
Complex [qlco] 0.000527386940821
Statins [orch, phsu] 0.000525079323291
Very [qlco] 0.000524636694914
Serious [qlco] 0.000523731301204
deaths [orgf] 0.000521927802151
admission [hlca] 0.000521185793616
Mechanisms [ftcn] 0.000520873459894
Delay [tmco] 0.000519928665448
Proportion [qnco] 0.000519581830328
Single [popg] 0.000519155280933
Appropriate [qlco] 0.000515771355425
Leading [tmco] 0.000514754405086
Severity [qlco] 0.000513743766995
Cost Effectiveness [qnco] 0.000513508736059
Then [tmco] 0.000513197099743
Observational Study [resa] 0.00051031705808
Future [tmco] 0.000510275284333
American [popg] 0.000510160861987
Seen [qlco] 0.00050939211918
Dietary [food] 0.000509299186903
Start [tmco] 0.000509201799598
Relation [famg] 0.000507263852286
confirmed [qlco] 0.000506830673053
conclude [bodm, orch] 0.000506484999795
Address [inpr] 0.000505578335294
Human [humn] 0.00050308977668
Male [fndg] 0.000502890703607
Measure [qnco] 0.000501891498618
Adults [aggp] 0.000500565390433
Hormone Replacement Therapy, Post-Menopausal [topp] 0.000499352000225
Asymptomatic [fndg] 0.000496316392267
admitted [hlca] 0.000495408370756
Elevated [qlco] 0.000494833068965
Initiate [idcn] 0.000494144426329
Frequent [tmco] 0.00049396920658
Correlated [qlco] 0.000493649251751
Sample [sbst] 0.000493472061796
Status [qlco] 0.000493350765869
prospective [resa] 0.000492926972501
Assigned [ftcn] 0.000491720568368
Involved [ftcn] 0.000491171483754
Altered [ftcn] 0.000490918679273
Class [inpr] 0.000489160757626
Contribute [acty] 0.00048812954854
density [qnco] 0.000486732772849
Medication [phsu] 0.000484678531321
Calcium [bacs, elii, phsu] 0.000484024266656
topic9
Estrogen [horm, phsu, strd] 0.00467690699932
Menopause [phsf] 0.00358662793279
Acute myocardial infarction [dsyn] 0.00311071098944
Subject [grup] 0.00305618979607
Breast Cancer [neop] 0.00272671688869
coronary artery disease [dsyn] 0.00267756405334
Old [tmco] 0.00258104298943
placebo [topp] 0.00242790812961
Drug [phsu] 0.00239789690962
Current [tmco] 0.00225093520295
Blood Pressure [orgf] 0.00224183125059
N NOS [aapp, imft] 0.00212563088767
Men [popg] 0.00209627098997
Incidence [qnco] 0.00208110897358
coronary [bpoc] 0.00206543820706
Myocardial Infarction [dsyn] 0.00201094742263
Change [ftcn] 0.00199055054083
Benefit [qnco] 0.00196530798863
randomized [resa] 0.00192947112109
Cholesterol [bacs, strd] 0.00189476841299
Similar [qlco] 0.00186410132106
Decrease [qlco] 0.00182375738848
Diabetes [dsyn] 0.00176456651432
Profile [lbpr] 0.00176146004291
ischaemic heart disease [dsyn] 0.00174650861245
mg% [qnco] 0.0017419850566
Possible [qlco] 0.00172499026037
Receive [qlco] 0.00172382705392
days [tmco] 0.00171668678822
Oral [spco] 0.00169803241735
Improved [qlco] 0.00169115984877
Dose [qnco] 0.00165641008723
acute [tmco] 0.00164074320367
Diet [food] 0.00163300133862
Plasma [bdsu] 0.00163157509136
Death [orgf] 0.00159625501365
Drugs [phsu] 0.00159521232954
diabetic [fndg] 0.00158703252426
Estradiol [horm, phsu, strd] 0.00157802153632
Combined [qlco] 0.00156745943269
Lipid [lipd] 0.00151694744231
Received [qlco] 0.00151568748753
Reported [inpr] 0.00151344652083
Decreased [qnco] 0.00150246744398
Equal [qlco] 0.00149889372702
Osteoporosis [dsyn] 0.00149068391664
Stroke [dsyn] 0.00148471461621
Drug Therapy [topp] 0.00146258314618
low [qlco] 0.00146255293175
Common [qnco] 0.00144079807351
High Risk [qlco] 0.00143307663286
Individual [popg] 0.00142453369251
Science [ocdi] 0.00140496653371
Users [humn] 0.00139230321558
Cancer [neop] 0.00138342078817
Overall [inpr] 0.00137166919282
Recent [tmco] 0.00136760767212
Survival [acty] 0.00134833496259
Improvement [cnce] 0.00133379383044
Early [tmco] 0.00132820155422
Total Cholesterol [lbpr] 0.0013225000848
Known [qlco] 0.00129123444586
Available [ftcn] 0.00129021086756
Likely [qlco] 0.00128235562102
Combination [qlco] 0.0012756686781
lowering [spco] 0.00126634142974
Hospital [hcro, mnob] 0.00126328964533
Benefits [qnco] 0.00125801023477
recommendations [idcn] 0.00125639206708
findings [ftcn] 0.00125349592545
Estrogen Replacement Therapy [topp] 0.00123834213061
Care [acty] 0.00123044295828
Non [ftcn] 0.00122938388884
Cases [ftcn] 0.00122181940356
Complications [patf] 0.00121537830415
Aged [orga] 0.00121361073565
Progestin [horm, phsu, strd] 0.00120613303213
Sex [orgf] 0.00119812912469
Agent [chvf] 0.00118795462082
Heart disease [dsyn] 0.00118474277294
PREVENT [phsu] 0.00117570227009
History [ocdi] 0.00116886998505
Previous [tmco] 0.00115947012824
Prevalence [qnco] 0.00115892971797
APPEAR [qlco] 0.00115568434063
Target [ftcn] 0.00115367668901
Large [qnco] 0.00114644543072
Confidence Interval [qnco] 0.00114525070092
Purpose [ftcn] 0.00114224510891
Following [tmco] 0.00114061983607
Guidelines [inpr] 0.00113784266278
condition [dsyn] 0.00113568050352
Conduct [inbe] 0.00112935721847
Range [qnco] 0.00112596160238
Atherosclerosis [dsyn] 0.00112464136162
Low Density Lipoprotein Cholesterol [bacs, strd] 0.00112355247545
symptoms [ftcn] 0.00112161328196
Triglycerides [bacs, lipd] 0.0011201502132
Null [qnco] 0.00111976741338
development [phsf] 0.00111969035288
Parameters [fndg] 0.00111722503802
Measured [qlco] 0.00111030083727
considered [idcn] 0.00110983668441
Well [qlco] 0.00110214199819
Estrogens [horm, phsu, strd] 0.00109958510828
Occur [acty] 0.00109949359552
practice [menp] 0.00109658530554
Continuous [idcn] 0.00109199220109
Alone [qnco] 0.00108804735765
Smoking [inbe] 0.00107874341888
Therapeutic [topp] 0.00107789536623
Main [qlco] 0.00107101037178
Secondary Prevention [topp] 0.00106413888851
activity [dora] 0.00106077299824
radiotherapy [inpr] 0.00105548307712
Odds Ratio [qnco] 0.00104815383764
Daily [tmco] 0.00104078515154
Take [hlca] 0.00102486949873
Quality [qlco] 0.00102307866646
Relative Risk [qnco] 0.00101779539932
Heart [bpoc] 0.00101464635327
Association [menp] 0.00100461859362
Events [evnt] 0.00100456004388
Specific [qlco] 0.00100392878795
Primary [qlco] 0.00100154652634
Provide [acty] 0.00100073147981
Diagnosis [fndg] 0.00099923156767
Induced [ftcn] 0.000994807701067
Four [qnco] 0.000993428102575
Simvastatin [orch, phsu] 0.000989671950663
GIVEN [cnce] 0.000983799594605
Concentrations [menp] 0.000982506953586
mg dl [qnco] 0.000980964070091
Life [idcn] 0.000974103140339
Clinical Trials [resa] 0.00097020142327
investigated [ftcn] 0.000969970724351
Obesity [dsyn] 0.000963931347036
function [phsf] 0.000963423915819
Evaluated [ftcn] 0.00096149964048
setting [ftcn] 0.000960142046164
Predictor [idcn] 0.000958891821931
vascular [bpoc] 0.000951008461387
Aspirin [orch, phsu] 0.000948644616876
Insulin [aapp, horm, phsu] 0.000948153800747
Identified [qlco] 0.0009467359951
LTD [ortf] 0.000946466903639
Low density lipoprotein [aapp, bacs, lipd] 0.000940203809814
Future [tmco] 0.000937520676337
influential [idcn] 0.000937515721029
Currently [tmco] 0.000931989289987
Prognostic Factor [clna] 0.000927358060143
Cost [qnco] 0.000926096663102
Relationship [qlco] 0.00092198413942
Evaluation [ftcn] 0.00092170992883
Initial [tmco] 0.000921261618306
Several [qnco] 0.000918175122824
Systolic blood pressure [clna] 0.000917387672499
Addition [ftcn] 0.000914941451201
Raloxifene [orch, phsu] 0.000913089491032
intervention [hlca] 0.000909095375719
Percent [qnco] 0.000905031569999
HRT [topp] 0.000904735482053
Medical [ftcn] 0.000902553360424
Physicians [prog] 0.000898153369996
Out [spco] 0.000897827726682
weeks [tmco] 0.000890451803493
Marker [clna] 0.000883849539679
Need [qlco] 0.000883029970305
Independent [idcn] 0.000882058199029
Administration [ocac] 0.000880153753788
Values [qlco] 0.000879645007547
experience [menp] 0.000876264592509
Morbidity [qnco] 0.000872038990254
Literature [inpr] 0.000870562214364
Replacement [topp] 0.000866753024449
Assess [acty] 0.000863033399966
Relative [famg] 0.000857938837123
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000856889835468
Recently [tmco] 0.000856326550886
national [inpr] 0.000853306606406
Atrial Fibrillation [patf] 0.000845082601932
Needed [qlco] 0.000844074126258
participants [popg] 0.000833622508423
Tamoxifen [orch, phsu] 0.000833394697243
Elderly [popg] 0.000832922782831
Serum [bdsu] 0.000829254231478
Heart failure [dsyn] 0.000828284640767
Transdermal [ftcn] 0.000822239768476
Established [qlco] 0.000821423173685
mmol/L [qnco] 0.000816424379023
Information [idcn] 0.000816341972019
Increasing [ftcn] 0.000815985197736
System [ftcn] 0.000812778111622
Start [tmco] 0.000811829458732
Assessed [acty] 0.000801028205635
progression [patf] 0.000800416753462
Affect [menp] 0.00079962682043
Young [tmco] 0.000796751143321
Select [acty] 0.000792334558123
Fasting [fndg] 0.000791727123125
Action [ftcn] 0.000788940740255
Long [qlco] 0.00078784133017
Examined [fndg] 0.000786824115105
Severe [qlco] 0.000783442861489
I- [inch] 0.000779606027726
Compliance [qnco] 0.00077926232171
Presence [topp] 0.00077739357003
reviewed [inpr] 0.000775642515525
Thrombolytic Therapy [topp] 0.000771029522546
R- [spco] 0.000768908180898
Concentration [menp] 0.000768057180128
mmHg [qnco] 0.000767004550698
cardiovascular risk factor [dsyn] 0.000766924355145
Progestagen [horm, phsu, strd] 0.000764945004738
Dietary [food] 0.000762911988518
IMPACT [gngm] 0.000762885536788
Female [fndg] 0.000761284217006
Characteristics [qlco] 0.000761158103147
Lp(a) [aapp, bacs] 0.000757682960359
Obtained [ftcn] 0.000754789732532
Report [inpr] 0.000753412868961
interventions [hlca] 0.000750823223788
Measure [qnco] 0.000750379230157
Phase [tmco] 0.000748006117931
Body Mass Index [diap] 0.000743771410346
Article [inpr] 0.000741635414858
C-reactive protein [aapp, imft] 0.000740574487543
size [spco] 0.000738774688802
Comparison [acty] 0.000737849190561
Knowledge [inpr] 0.000737230536116
Support [medd] 0.000734966520645
Chemoprevention [topp] 0.00073393781472
Risks [qlco] 0.000730225403751
Estimated [qnco] 0.000720337390385
Response [orga] 0.000720153090525
Cardiac [bpoc] 0.000710695872311
Test [lbpr] 0.000706265020366
society [orgt] 0.00070583690437
United States [geoa] 0.000704304546382
Average [qnco] 0.000704115242571
Often [tmco] 0.000698864691115
Venous Thromboembolism [patf] 0.000698193636092
Prognosis [hlca] 0.000697557078199
Compound [qlco] 0.000694920965046
Cholesterol, LDL [bacs, strd] 0.000689438089621
variables [qlco] 0.000688665387004
Lipoprotein [aapp, bacs] 0.000687721614882
Make [ftcn] 0.000687470292288
Duration [tmco] 0.0006862636524
Approach [spco] 0.000682936762994
Case [ftcn] 0.000681498225479
Indicated [fndg] 0.000680516777596
Reducing [qlco] 0.000680235918615
Sample [sbst] 0.000677035951254
Diastolic blood pressure [clna] 0.000674809745478
Normal [qlco] 0.000673639611894
Dependent [qlco] 0.000673433780787
Onset [qlco] 0.000673385581298
Hypercholesterolaemia [dsyn] 0.000670577142843
Diabetes Mellitus [dsyn] 0.000670402043987
median [spco] 0.000668593494901
Mechanisms [ftcn] 0.000668323962832
objectives [inpr] 0.000667998565851
Children [aggp] 0.000666907591953
Now [tmco] 0.000666084737433
Part [spco] 0.00066367914617
Seen [qlco] 0.000663049378853
Menopausal [phsf] 0.000661688781164
Adjustment [inbe] 0.000660325700261
g% [qnco] 0.00065922925648
Plus [qlco] 0.000657472187434
Ireland [geoa] 0.00065657796275
Model [inpr] 0.000656570721213
smokers [fndg] 0.000654940202215
Issue [fndg] 0.000650720836773
Second [qnco] 0.000648900765992
Hormone [horm] 0.000645990567489
Effectiveness [qlco] 0.000643741674905
American [popg] 0.000641431927169
Medication [phsu] 0.000639438687314
Strong [qlco] 0.000638151847719
Equine [mamm] 0.000637206653573
Regimen [topp] 0.000637178168026
Controlled [ftcn] 0.000634664222356
hypertensive [fndg] 0.000633511049987
adverse effects [ftcn] 0.00063249060464
Syndromes, Acute Coronary [dsyn] 0.000630791385559
Surgery [bmod] 0.000629956782402
regimens [inpr] 0.000627599728867
Fibrinogen [aapp, bacs, phsu] 0.000627541809541
Lipids [lipd] 0.000626471170186
Method [inpr] 0.000626035610412
Cohort [popg] 0.000625975896585
Central [spco] 0.000624845132318
Costs [qnco] 0.000624368277736
Life Style [socb] 0.000618179357504
month [tmco] 0.000616823860104
Play [dora] 0.000616676275765
Late [tmco] 0.000616310317406
Limited [ftcn] 0.000614915853384
Diseases [dsyn] 0.000613337346934
Ischaemic [ftcn] 0.000610502861651
Thrombosis [patf] 0.000609547326376
Control Group [grup] 0.000608741034438
strategies [menp] 0.000608534421175
Administered [ftcn] 0.000607319715505
Address [inpr] 0.000604999904356
Infarction [patf] 0.000603177269895
Better [qlco] 0.000602591749037
.BETA.-Carotene [orch, phsu, vita] 0.000601895538255
Initiate [idcn] 0.000601759137955
Severity [qlco] 0.000601157235167
Recommended [idcn] 0.000600989209512
Human [humn] 0.000600405614322
Exercise [dora] 0.000599961738652
Stage [tmco] 0.000599521969862
Treatments [topp] 0.000596883901362
Same [qlco] 0.000595561503546
Additional [ftcn] 0.000593547944668
lack [qlco] 0.000593345478353
Sequential [idcn] 0.000589700329313
Defined [cnce] 0.000587203274409
Breast [bpoc] 0.000586622967546
Standard [qlco] 0.000585665558605
Ratio [qnco] 0.000584473615648
Estrogen Replacement [topp] 0.000584036212736
properties [qlco] 0.000583737673017
Progestins [horm, phsu, strd] 0.000583563835444
Concern [idcn] 0.000582807856533
Education [edac] 0.00058205368045
tibolone [phsu, strd] 0.000577421242905
Type [qlco] 0.000576273553856
Correlated [qlco] 0.000575094119639
Cholesterol, HDL [bacs, lipd] 0.000572155079238
In [qnco] 0.000571687761156
Lipoprotein (a) [aapp, bacs] 0.000571451131573
measurements [ftcn] 0.000569349886642
???lead [elii, hops] 0.000569332524072
Favorable [qlco] 0.000567871981455
cardiovascular events [fndg] 0.000566286123766
H+ [elii] 0.000565896775379
Endothelial [tisu] 0.000563209973897
Asymptomatic [fndg] 0.00056130651213
Question [inpr] 0.000560852390656
Calcium [bacs, elii, phsu] 0.000560229085973
Approaches [spco] 0.000560030722459
Contribute [acty] 0.000553591772592
Supplementation [topp] 0.000552502270369
density [qnco] 0.000552178178981
frequency [qnco] 0.000551706332166
Negative [qlco] 0.000550669872516
Physical activity [dora] 0.000546429486078
Lipid-lowering therapy [topp] 0.000545113393465
Past [tmco] 0.000544484101169
Five [qnco] 0.000544392385776
Event [evnt] 0.000543901831383
Lipoproteins [aapp, bacs] 0.00054354247352
Frequent [tmco] 0.000542530629819
Risk factor [qnco] 0.000540508151744
Mechanism [ftcn] 0.000540360374312
Half [qnco] 0.000539403493623
Understanding [menp] 0.000539328076246
Bleeding [patf] 0.000538756994333
Discussion [topp] 0.00053855655724
Alternative [cnce] 0.000538532177797
Beta-Blockers [phsu] 0.000532974655181
Required [ftcn] 0.000531713593966
Adults [aggp] 0.000531425031154
prognostic [inpr] 0.000531328497492
Cardiology [bmod] 0.000530223757171
mg day [qnco] 0.000529838970879
Program [cnce] 0.000529194421714
Status [qlco] 0.000526199342459
Observational Study [resa] 0.000525479167967
Ventricular arrhythmias [patf] 0.00052495646837
Exist [cnce] 0.000524618779815
admitted [hlca] 0.000523664712936
mediated [socb] 0.000523221198622
Weight Gain [fndg] 0.000523017208463
adverse events [fndg] 0.000521677481412
Various [irda] 0.00052108464598
Thrombolysis [clna] 0.000519572280807
Consecutive [qlco] 0.000519398465825
Occurred [acty] 0.000518898238328
Modification [ftcn] 0.000518254672233
Complex [qlco] 0.000517506505881
occurrence [ftcn] 0.000514647998548
Documented [hlca] 0.000513276620569
Single [popg] 0.000512363660372
Woman [popg] 0.000510506876596
Conjugated estrogen [horm, phsu, strd] 0.000509542418914
Then [tmco] 0.000508372412633
Few [qnco] 0.000507521254183
Adjusted [ftcn] 0.000506485573952
Cost Effectiveness [qnco] 0.000504960488817
Insulin Sensitivity [patf] 0.000503635896126
medroxyprogesterone acetate [horm, phsu, strd] 0.000502983566956
Formulation [resa] 0.000502534561193
Ii [aapp] 0.000502147404541
Center [spco] 0.000500116245689
